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SUMMARY STATEMENT 
Beta-blockers are avoided in asthma and chronic obstructive pulmonary disease  
(COPD) due to the potential risk of drug induced bronchospasm. Despite these 
concerns, beta-adrenoceptor antagonism has recently been associated with potential 
therapeutics benefits in asthma. Furthermore the use of beta-blockers in COPD patients 
may potentially result in improved survival due to optimisation of treatment in those 
with concurrent cardiovascular disease.   This thesis evaluates the role of beta-blocker 
use in asthma and COPD. 
 
The introduction outlines the pharmacological principles associated with the human 
beta-adrenoceptor and its therapeutic application in the management of asthma and 
COPD through established treatment strategies including inhaled beta-agonists. The 
historical literature documenting concerns with beta-blocker use in asthma and COPD is 
reviewed and critiqued. Finally the hypothesis, on which this thesis is based, that beta-
blockers may have a therapeutic role in the asthma and COPD is discussed. Proof of 
concept studies and preliminary work suggesting potential putative effects of beta-
blocker use in asthma, data highlighting the burden of cardiovascular disease in COPD 
patients and the potential role of beta-blockers are discussed. 
 
New data from two randomised double-blind placebo controlled trials evaluating beta-
blocker use in asthma and an observational study investigating the effects of beta-
blocker use on mortality in COPD are presented.    The first randomised controlled trial, 
addresses the safety of beta-blocker use in asthma. Using the non-selective beta-blocker 
propranolol, the study investigated the safety of acute exposure to propranolol in 
asthmatics, sequentially challenged with histamine to mimic an asthma exacerbation 
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and evaluated the role of intravenous hydrocortisone in potentiating salbutamol 
reversibility. The results of this study showed there was no significance difference in 
salbutamol recovery measured by change in FEV1 (ml) post histamine challenge 
following intravenous hydrocortisone verses placebo (mean difference 0.04 (95%CI -
0.07 to 0.15), p=0.417). 
 The study also investigates the degree of bronchoconstriction attributable to oral 
propranolol in mild-to-moderate asthmatics and uses impulse oscillometry as an 
alternative method of assessing pulmonary function to conventional spirometry.  
Following 10 or 20mg of oral propranolol, a mean fall in FEV1 of 4.7% was observed 
(95%CI 1.8 to 7.5), p=0.008. Impulse oscillometry showed a greater response to 
propranolol with an increase of 31.3% (95%CI 15.6 to 47), p= 0.04, 2 hours post 
propranolol dosing. 
 
The second randomised controlled trial within this thesis, describes the first placebo-
controlled trial to assess the effects of chronic dosing with oral propranolol as add-on to 
inhaled corticosteroids in patients with stable persistent asthma.  The study investigated 
the hypothesis of potential therapeutic benefits of chronic beta-blocker use in asthma by 
improvements in airway hyper-responsiveness. This study evaluates the effects of oral 
propranolol on both methacholine and histamine bronchial challenges, in addition to 
spirometry, impulse oscillometry and inflammatory surrogates including exhaled nitric 
oxide. Furthermore the effects on asthma control and quality of life post chronic beta-
blockade are described.  Finally the safety and tolerability of acute cardio-selective 
beta-blockade with esmolol is compared to acute propranolol dosing and the protective 
effects of tiotropium are evaluated. 
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The main result of this study showed chronic propranolol dosing did not affect airway 
hyper-responsiveness, with no significant difference observed in methacholine 
challenge PC20 following chronic propranolol exposure compared to placebo, geometric 
mean mg/ml: 2·57 (95%CI 1·13 to 5·85) versus 2·50 (95%CI 1·14 to 5·50), -i.e. a mean 
doubling dilution difference (DDD) of 0·04 (95%CI -0·56 to 0·63), p=0·89.  
Furthermore following chronic beta-blocker dosing, FEV1 showed a fall with 
propranolol versus placebo amounting to a 4·3% (95%CI -0·6 to 9·2) p=0·08 
 
The final study within this thesis is a large observational cohort study using a disease 
specific dataset of COPD patients. By means of data linkage using pharmacy 
prescriptions, hospital admissions and mortality data, the potential effects of beta-
blocker use on COPD exacerbations and mortality is examined.  This study suggested a 
potential survival benefit with beta-blocker use amounting to a 22% reduction in 
mortality (HR 0.78 (95%CI 0.67 to 0.92). 
 
The discussion of this thesis evaluates the results of each study and describes their 
relevance in the management of patients with asthma and COPD. 
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CHAPTER 1: 
INTRODUCTION 
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1. BETA-RECEPTOR FUNCTION 
 
 
a. THE HUMAN BETA-RECEPTOR 
 
In 1948 Ahlquist classified receptors of the sympathetic nervous system into two 
distinct groups: alpha and beta.1 Two decades later Lands et al. further subdivided the 
beta-adrenoceptors into subtypes: groups 1 and 2.2 Latterly the beta-3 subtype has also 
been identified.3 Beta-adrenoceptors are distributed throughout the human body with 
differing effects at each location (see table 1). Although beta-1-adrenoceptors are found 
in the lungs within alveolar walls and submucosal glands, stimulation of beta-1-
adrenoceptors to circulating noradrenaline and adrenaline, predominantly affects the 
heart resulting in an increased chronotropic and inotropic effect. 
 
Within the human lung, the beta-2-subtype account for approximately 70% of beta-
adrenoceptors.4,5 Autoradiographic mapping has shown that the beta-adrenoceptors seen 
in airway smooth muscle from both the large and small airways are entirely of the beta-
2-subtype.5 Furthermore beta-adrenoceptors found in airway epithelium and vascular 
smooth muscle are also entirely of the beta 2-adrenoceptor subtype. There is a uniform 
distribution of beta-adrenoceptors on the alveolar wall with a ratio of beta-1: beta-2 
adrenoceptors of 2:1.6 These findings are confirmed by in situ hybridization studies that 
have shown a similar distribution of beta-1 and beta-2 adrenoceptor mRNA in human 
lung tissue.7,8 
The beta-2-adrenoceptor preferentially binds to adrenaline rather than nor-adrenaline, 
primarily due to the lack of noradrenergic innervation of human bronchial smooth 
muscle.  Although there is no direct sympathetic innervation of human bronchial 
muscle, pre-junctionally, the sympathetic neurons lie close to the parasympathetic 
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neuron and are thought to influence beta-2-adrenoceptors here thus resulting in 
sympathetic modulation of cholinergic innervation. This phenomenon of beta-2-
adrenoceptor and muscarinic receptor crosstalk,9 may account for the ability of anti-
cholinergic medications to inhibit beta-blocker induced bronchoconstriction in asthma.10 
11 
The affinity to adrenaline is also thought to be due to the size and location of the ligand 
binding site on the beta-2-adrenoceptor.12 Although found predominantly in airway 
smooth muscle, beta-2-adrenoceptors are found throughout human lung tissue, and are 
also found epithelium, vascular smooth muscle and submucosal glands.6 Latterly a third 
group of beta-adrenoceptors has been identified which is different to the beta-1 and 
beta-2 subtypes. The beta-3-adrenoceptor   or   “atypical   beta-receptors”   has   been   found  
predominantly within adipose tissue and is yet to be identified within pulmonary 
tissue.13 
SUBTYPE LOCATION  PHYSIOLOGICAL EFFECT 
Beta-1 Heart Increased Myocardial 
Contractility 
 Hypothalamus Increased Renin Release 
 Kidney (Juxtaglomerular cells) 
 Brain and Coronary Vessels Vasodilatation 
 Alveoli Increased alveolar fluid clearance 
 
Beta-2 Alveolar Epithelium Increased alveolar fluid clearance 
 Bronchial Epithelium  
 Airway smooth muscle Bronchodilatation 
 Skeletal muscle Increased potassium uptake 
 Vascular smooth muscle Vasodilatation 
 Liver Increased glucose metabolism 
  Increased lipolysis 
 Uterus Relaxation 
 GI Tract Decreased motility 
 Gall Bladder Relaxation 
 Detrusor muscle (bladder) Relaxation 
 Eye ciliary muscle Relaxation 
DS 
Beta-3 Adipose tissue Increased lipolysis 
 
Table 1. Subtypes of beta-adrenoceptors 
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b. ROLE OF THE BETA RECEPTOR IN THE MANAGEMENT OF 
AIRWAY DISEASE 
 
The human beta-adrenoceptor is a member of the seven-transmembrane family of 
receptors encoded by a gene on chromosome 5.14 Through the means of coupling with a 
Gs protein, (which consists of the subunits D,E, and J) to adenylate cylase there is a 
subsequent activation of intracellular cyclic adenosine monophosphate (cAMP). Beta-
adrenoceptors exist in both an active and inactive form, and at rest the inactive form is 
predominant.  The beta-adrenoceptor is in the activated form when associated with the 
D subunit of the G protein in associated with guanosine triphosphate (GTP) and it is 
through this D subunit that it is coupled to adenylate cyclase.14 GTP is then replaced by 
guanosine diphosphate  (GDP) which subsequently catalyses the conversion of 
adenosine triphosphate (ATP) to cAMP.  Furthermore the presence of GDP reduces the 
affinity of the D subunit for the beta-2-adrenoceptor causing it to return to its inactive 
form. 
 
Within the lung the beta-2-adrenoceptor are found within varying cell types. 
Predominantly found within airway smooth muscle, they are also found in mast cells, 
post capillary venular endothelial cells, airway sensory nerves and inflammatory cells 
(including eosinophils, neutrophils, macrophages and T-lymphocytes). Stimulation of 
the beta-2-receptor with subsequent effects on cell function can occur primarily by 
means of binding to endogenous ligands, such as adrenaline or by the use of beta-
agonists, such as salbutamol. 
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Airway smooth muscle relaxation 
Release of cAMP causes airway smooth muscle dilatation by activation of protein 
kinase A (PKA) which causes phosphorylation of several proteins resulting in muscle 
relaxation.15 cAMP also results in inhibition of calcium release, due to reductions in 
intracellular calcium stores, thus resulting in smooth muscle dilatation.  Although 
cAMP is responsible for a significant bronchodilatory effect, pathways independent of 
cAMP, including interaction of the Gs protein D subunit with potassium channels within 
the airway smooth muscle result in muscle relaxation.16  Furthermore beta-receptors can 
also bind to Gi proteins, resulting in stimulation of the mitogen-activated protein (MAP) 
kinase pathway with subsequent airway dilatation. 14 
 
Effects on inflammatory cells 
Stimulation of the beta-adrenoceptor, by means of beta-agonists has been shown to 
inhibit the release of histamine and cysteinyl-leukotrienes within human mast cells.17 
Beta-agonists have also been shown to have a greater bronchoprotective effect against 
adenosine-monophosphate induced bronchoconstriction, which is mediated by mast cell 
degranulation in comparison to methacholine, which has direct bronchoconstrictor 
effects on airway smooth muscle.18 This finding implies that beta-agonists may have 
mast–stabilising effects. 
 
Beta-2-adrenoceptors have been identified in eosinophils, neutrophils, T lymphocytes 
and macrophages.6,19 Whilst use of acute beta-agonists has been shown to inhibit release 
of inflammatory mediators, chronic beta-agonist use results in tolerance and down-
regulation of the beta-receptor, meaning this benefit cannot be sustained.6 
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Effects on vascular permeability 
Leakage of plasma from postcapillary venules is a hallmark of acute inflammation. 
Although data within asthma and COPD is poorly defined regarding the significance of 
airway vascular leakage, airway microcirculation is known to be abnormal in asthma.20 
To this effect beta-agonists have been shown to inhibit plasma exudation, suggesting 
acute anti-inflammatory effects in the airway.21 
 
Airway Sensory Nerves 
Beta-agonists have been shown to modulate neurotransmission via pre-junctional 
receptors on airway nerves.22 Acute beta-agonist use has been shown to inhibit 
bronchoconstrictor responses from neuropeptides released from sensory nerves 
mediated via beta-2-receptors in guinea pigs.23 The importance of sensory nerves with 
asthma in human subjects is still uncertain.24 
 
Epithelial cells 
There is a high density of beta-2-adrenoceptors in airway epithelial cells.25 Epithelial 
cells can secrete a wide variety of inflammatory mediators in response to allergens and 
viruses, which may result in airway remodeling.26  Migration of Th2 helper cells to the 
lung is key to their inflammatory function in asthma. Th2 helper cells lacking   β-
arrestin-2, a G protein–coupled receptor regulatory protein, demonstrate impaired 
migration in vitro. Furthermore in allergen-sensitized mice having a targeted deletion of 
the beta-arrestin gene do not accumulate T lymphocytes in their airways, thereby having 
reduced airway inflammation. This evidence supports the possibility of the beta-arrestin 
pathway being a pro-inflammatory pathway activated by beta-2-adrenoceptors in 
asthma.27,28 
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Extra-pulmonary effects 
Although the major effects of activation of beta-2-adrenoceptors are bronchodilatation 
of the human airway, stimulation of extra-pulmonary beta-2-adrenoceptors influences 
the regulation of serum potassium. This is achieved by several mechanisms.  Within the 
kidney, beta-2-adrenoceptor stimulation by circulating catecholamines results in 
increased renin levels, with subsequent aldosterone synthesis and potassium excretion.29  
Extra-renal augmentation of potassium load is also influenced by beta-2-adrenoceptor 
stimulation, with increased cellular uptake of potassium occurring predominantly within 
skeletal muscle.29 Skeletal muscle regulates extracellular potassium by means of the Na-
K-ATPase pump.30 By means of beta-2-adrenergic stimulation, by either circulating 
nor-adrenaline or beta-2-agonists, the formation of cyclic AMP, acts through protein 
kinase A to phosphorylate and activate the Na-K-ATPase pump, leading to the influx of 
potassium into cells. Conversely the competitive inhibition of the beta-2-adrenoceptor 
by beta-blockade decreases Na-K-ATPase function and reduces potassium uptake by 
cells.31  In a study by Rosa et al, the regulation of potassium homeostasis by beta-
adrenergic stimulation was studied. In 9 healthy volunteers, given intravenous 
potassium, the addition of propranolol augmented and prolonged elevation of serum 
potassium without decreasing urinary potassium excretion.29  
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c. BETA-AGONISTS AND BETA-BLOCKERS 
 
Receptor pharmacology 
There are two fundamental properties requiring clarification prior to discussing 
adrenoceptor-ligand interactions. Affinity describes the ability of the ligand to bind to 
the receptor and efficacy describes the ability of the ligand-receptor complex to induce a 
response. Selectivity to a receptor, for example beta-1 and beta-2 selective medications 
is based upon the degree of affinity to the chosen receptor. 
 
Ligands at the beta-adrenoceptor are classified as agonists or antagonists based upon the 
presence of efficacy. Furthermore the degree of efficacy present allows for further 
classification. 
 
A full agonist has a similar response to that of the endogenous ligand and therefore 
displays maximal efficacy. A partial agonist also binds and activates the receptor 
however but only has partial efficacy relative to a full agonist. 
 
A neutral antagonist binds at the receptor but does not have any efficacy, and does not 
result in any receptor activity. In reality the majority of medications considered to be 
antagonists do stimulate a response, whether this is as a weak partial agonist or an 
inverse agonist.32  A prerequisite for an inverse agonist, is that the receptor must have a 
degree of constitutional activity in the absence of any ligand. Whilst an agonist 
increases the activity of a receptor above basal level, an inverse agonist decreases the 
activity   below   basal   level   and   essentially   “switches   off”   the   receptor,   thus   displaying 
negative efficacy (figure 1). 
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Figure 1. Dose response curves of a full agonist, partial agonist, neutral antagonist and inverse agonist. 
(Figure from Wikimedia commons, http://en.wikipedia.org/wiki/File:Inverse_agonist_2.png. Figure has 
free license for reproduction.)  
 
 
Beta-agonists 
The emergence of inhaled beta-2-agonist medications, simulating the effects of 
endogenous ligands provided a pharmacological means of targeting the beta-2-
adenoceptor in the lungs, and thus achieving bronchodilatation.  The development of the 
beta-2-agonist drug class has since become established as a cornerstone in the 
pharmacological management of asthma and COPD.33,34 
 
Following the discovery by Lands et al, regarding the distinction between beta-1 and 
beta-2 subtypes,2 investigators began to attempt to develop a medication which exerted 
bronchodilatory effects on the lungs whilst having minimal effects on the heart.  
Discovered independently in the late 1960s, salbutamol and terbutaline were the first 
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beta-2-adrenoceptor agonists found to have significant acute bronchodilatory effects in 
the absence of significant cardiac stimulation.35,36 
 
Whilst salbutamol and terbutaline have relatively short duration of actions, following 
the search for long acting beta-2-agonists, both salmeterol and formoterol were 
developed. Whilst salmeterol and formoterol both display similar degrees of affinity for 
the beta-2-adrenoceptor, formoterol has a higher efficacy thus accounting for its faster 
onset of action.32 The development of long acting beta-agonists revolutionised the 
treatment of asthma and COPD thereby providing means of achieving a sustained 
bronchodilatory effect of approximately 12 hours in comparison with the approximate 
4-6 hours bronchodilatory effects of salbutamol and terbutaline.37,38 
 
Whilst long-acting beta-agonists (LABA) undoubtedly improved the treatment of 
airway disease, there are concerns in asthma that sustained use of long-acting beta-
agonists may results in beta-adrenoceptor tachyphylaxis and tolerance. Tachyphylaxis is 
defined as describing an acute (sudden) decrease in the response to a drug after its 
administration. Tachyphylaxis can occur both after an initial dose of medication or after 
an inoculation with a series of small doses. Increasing the dose of the drug may be able 
to restore the original response. This phenomenon known as tachyphylaxis or 
desensitization is exhibited upon exposure of cells to beta-adrenergic catecholamines 
resulting in a progressive, often rapid, loss in subsequent responsiveness of the 
adenylate cyclase system to further catecholamine stimulation.39  In addition to 
desensitization, down-regulation of the beta-adrenoceptor can occur, describing the 
process of actual receptor loss following persistent catecholamine stimulation.40 
Beta-adrenoceptor desensitization and down-regulation does have clinical relevance 
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with chronic beta-agonist therapy in asthmatic subjects resulting in reduction in beta-
adrenoceptor density in circulating polymorphonuclear leukocytes and lymphocytes.41 
Sustained beta-agonist stimulation has also been shown in asthma to cause progressive 
diminution of the agonist response in the form of a reduced bronchoprotective effect to 
bronchial challenge testing.42,43 Furthermore in asthma there has been concern that 
regular use of LABAs had a detrimental effect on asthma control,44 whilst the 
Salmeterol Multi-center Asthma Research trial (SMART study) even reported increased 
risk of mortality.45  Whether or not inhaled corticosteroids given concurrently with 
LABAs mitigate these risks is uncertain.   
 
In a study by Mak et al, the in vivo effects of glucocorticoids on beta-agonist induced 
down-regulation of beta-1 and beta-2-adrenoceptors were studied.46 Chronic treatment 
of dexamethasone was associated with an increased density of beta-1 and beta-2 
adrenoceptors and an increase in the transcription rate of the beta-2-adrenoceptor gene.  
These changes were in comparison with an observed reduction in beta-1 and beta-2 
adrenoceptor density following chronic dosing with the beta-agonist, isoproterenol. 
Combined treatment of glucocorticoids and isoproterenol resulted in no net change in 
beta-2-adrenoceptor density, thereby implying that glucocorticoids prevent beta-
adrenoceptor down–regulation, by augmenting gene transcription which in turn could be 
suggested to prevent tachyphylaxis.46 Also in humans, high dose systemic 
corticosteroids have been shown to re-establish the beta-2-adrenoceptor function 
following agonist promoted down-regulation. These effects were seen in patients 
already taking inhaled corticosteroids.47 These concerns however have resulted in the 
FDA advising that long-acting beta-agonists should not be given as monotherapy in 
asthma, suggesting they should only be used in addition to inhaled corticosteroids.48 
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Beta-adrenoceptor polymorphisms have been suggested as a potential cause of variable 
response to beta-agonists in individuals.  The greatest attention has been given to single 
nucleotide polymorphism causing amino acid substitutions within the beta-2-
adrenoceptor at position 16.  Individuals homozygous for arginine (Arg /Arg) in 
comparison with those homozygous for glycine (Gly /Gly) have been found to have an 
improved peak expiratory flow when chronic dosing with salbutamol has been replaced 
with the short acting muscarinic antagonist ipratropium.49 Further evidence of the 
importance of the Arg16 genotype is seen by in 164 asthmatic children taking inhaled 
corticosteroids and salmeterol, there was an 3.4 fold (95%CI 1.19 to 9.4) increased risk 
of asthma exacerbations when comparing Arg16 with Gly16 patients.50 Although the 
SMART study did not stratify participants by genotype, it did indicate that the risk of 
death was greater in those of African American descent. Therefore although it is not 
possible to draw conclusions with regards to the influence of genotype on mortality 
within the SMART study, African Americans are known to have an increased frequency 
of the Arg16 polymorphism.51 
 
The LARGE trial published in 2009, attempted to answer conclusively in a placebo 
randomised controlled trial design whether there was a genotype-specific response to 
treatment with a long-acting beta-2-agonists in combination with inhaled corticosteroid.  
The study concluded that there were beneficial effects on pulmonary function in both 
Arg16 homozygous and Gly16 homozygous participants, with improvements seen in 
both groups in morning peak expiratory flow in comparison with placebo.52 However 
within the study, Gly16 homozygous participants had a 2.4 fold greater improvement in 
airway hyper-responsiveness (AHR) with salmeterol compared to placebo (p<0.001), 
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while participants homozygous for Arg16 showed no benefit in AHR in comparison to 
placebo.52 It could therefore be postulated that in clinical practice, assessing individuals 
risk by testing individuals for genetic polymorphisms may be important when 
considering LABA therapy in asthma.53 
 
Interestingly no concerns regarding LABA monotherapy exist in COPD, presumably 
due to the lack of significant airway hyper-responsiveness in the condition. Clinical 
studies have shown that LABA therapy in COPD improves lung function, reduces 
symptoms of breathlessness and exercise limitation, health related quality of life and 
may reduce exacerbations.38 Furthermore no increased risk of mortality with LABA 
monotherapy was seen in the, Towards a Revolution in COPD Health (TORCH) study, 
over a period of 3 years.54 
 
Beta-blockers 
In 1964 the beta-antagonist (or beta-blocker), propranolol was released for the treatment 
of cardiovascular disease following its discovery by the late Nobel Laureate Sir James 
Black.55,56 Following the sudden death of his father from a presumed heart attack, Sir 
James wanted   to   “stop   the   effects   of   adrenaline”   on the heart, proposing that by 
blocking the effects of catecholamines would result in a reduction in cardiac stress, with 
decreased workload and subsequent anti-anginal effects.57 This discovery revolutionised 
the management of cardiovascular disease with beta-blockers now routinely given for 
treatment of hypertension, heart failure and post myocardial infarction.58 
 
Beta-blockers are primarily classified based upon beta–receptor affinity. Propranolol 
has similar affinity for both beta-1 and beta-2 adrenoceptor and therefore is classed as 
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non-selective.59 Other examples of non-selective beta-blockers include carvedilol, 
nadolol and sotalol. However all classed as non-selective each of these medications 
have a preferential selectivity for the beta-2 adrenoceptor, varying from carvedilol with 
a 4.5 fold affinity to beta-2, propranolol 8.3 fold affinity and nadolol 23.4 fold affinity.59 
Similarly so called cardio-selective beta-blockers have been developed with varying 
degrees of beta-1 selectivity.60  However despite their name, none in clinical use are that 
beta-1 selective, with bisporolol being the most selective with a 13.5 fold affinity to the 
beta-1-adrenoceptor.59,60 This is in comparison with the beta-agonists salbutamol and 
salmeterol being 28.8 and 2818.4 fold selective to the beta-2-adrenoceptor.59 
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2. HISTORICAL PERSPECTIVE OF BETA-BLOCKER 
USE 
 
a. BETA-BLOCKER USE IN AIRWAYS DISEASE 
 
Despite the emerging role for beta-blockers in the treatment of cardiovascular disease 
this was accompanied by concerns regarding beta-blocker use in patients with airway 
disease. The greatest concern was found in asthmatics due to antagonism of the beta-2-
adrenoceptor, resulting in unopposed parasympathetic bronchoconstriction thereby 
limiting their use. To date prescription of beta-blockers in patients with asthma or 
COPD would be in contradiction with accepted clinical practice. 
 
The concern regarding beta-blocker primarily in asthma was addressed through a small 
number of clinical trials looking at the interaction of beta-blockers and asthmatics and a 
series of case reports illustrating potential adverse effects. These findings have 
subsequently influenced beta-blocker use in both asthma and COPD. 
 
In 1964 whilst based in Maryfield Hospital (Dundee, UK) McNeill assessed the effects 
of intravenous propranolol in a group of 10 asthmatic patients.61   Administration of 5-
10mg intravenous doses of propranolol, resulted in a fall in forced expiratory volume in 
1 second (FEV1) on average of 23% (range 6% to 56%). However looking at individual 
response following propranolol, 60% of patients had no significant fall in their FEV1 
measurements post propranolol when comparing baseline measurements to final 
measurements that varied from 60-90 minutes post propranolol.61 Infact with 
intravenous propranolol having a distribution half-life of approximately 5-10 minutes, 
comparing the maximal fall in FEV1 15 minutes post propranolol 60% of participants 
have FEV1 falls comparable with the physiological variation of the test (see figure 2). 
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Figure 2. Fall in FEV1 15 minutes post intravenous propranolol. (Derived from McNeill et al).61 
 
Two years later, Zaid and Beall investigated the effects of serial bronchial challenges 
with histamine and methacholine (mean dose 4.5mg) before and after an intravenous 
injection of 0.1mg/kg of propranolol.62 Three distinct patient groups were involved in 
this study: normal subjects, patients with allergic rhinitis and patients with asthma.  
Each individual underwent bronchial challenge testing with a fixed dose of histamine or 
methacholine. Following this their FEV1 was compared to baseline measurements. 
Individuals were then allowed to recover and then were administered intravenous 
propranolol and FEV1 measurements were recorded, prior to being rechallenged with 
histamine or methacholine with their FEV1. Normal subjects and rhinitis patients had no 
greater sensitivity to histamine or methacholine following either bronchial challenge 
testing or propranolol.  In contrast in the group of asthmatics mean FEV1 measurements 
fell by 16.6% after initial challenge testing, 9.1% post propranolol and by 29.6% with 
the rechallenge that followed propranolol administration (see figure 3).62 
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Figure 3. Fall in FEV1 post subcutaneous methacholine versus iv propranolol.  
Data displayed as mean (SEM).  (Derived from Zaid and Beall).62 
 
At this time it was hypothesised that an intrinsic imbalance of beta-adrenergic receptor 
function may have been the pathophysiological cause of bronchoconstriction. Despite 
partial beta blockade in healthy controls the lack of increase in bronchial sensitivity to 
histamine or methacholine allowed the investigators to conclude that beta-blocker 
induced bronchoconstriction was specific to asthmatic individuals. These findings 
showed that although beta-blocker induced bronchoconstriction was a major concern in 
asthmatics, the pathophysiological cause of asthma was more complicated than simple 
blockade of the beta-receptor. 
 
The study by Zaid and Beall served to highlight the relative falls in FEV1 following the 
commonly used methacholine bronchial challenge agent compared to beta blockade.62 
To further demonstrate the comparative effects of methacholine induced 
bronchoconstriction and propranolol, in a study by Ind et al, showed inhaled 
propranolol to be less potent at bronchoconstriction than inhaled methacholine with a 
geometric mean dose causing a 35% fall in airway conductance of 4.7µmol for 
propranolol compared with 0.48 µmol for methacholine.10 
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The ability to reverse the bronchoconstriction provoked by beta-blockade has been 
questioned as a major concern with extremely high doses of salbutamol being 
required.63  Ind et al however showed that the use of the anticholinergic oxitropium has 
been shown to reverse the bronchoconstriction caused by acute beta-blockade with 
propranolol.10 
 
The identification of the beta-1 and beta-2 receptor subtypes by Lands et al in 1967, 
resulted in controlled trials being performed with non-selective beta-blockers which 
affinity for both beta-1 and beta-2 receptors such as propranolol and specific beta-1-
receptor antagonists focussing upon individualised effects on pulmonary function. 
 
Developing on their previous work, McNeill and Colleagues compared the effects on 
airway resistance of single dosing with intravenous propranolol and an intravenous 
selective beta-1-antagonist called ICI.50,172. 64  Airway resistance (AWR) measured 
via body plethysmography and FEV1 were recorded.  Propranolol was shown to be 
significantly worse in increasing airway resistance with a mean increase of 176% in 
comparison with 23% with ICI.50,172 (see figure 4). The difference with FEV1 
mirrored the trend seen with AWR with a mean fall in FEV1 post propranolol of 44% in 
comparison with a fall of 9% post ICI.50,172. 
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Figure 4. The effect of 5mg propranolol versus 15mg ICI.50,172 on airway resistance. Data displayed as 
Mean (SEM). (Derived from MacDonald et al).64 
 
Johnson et al investigated the effects of intravenous propranolol and the selective beta-
1-adrenoceptor antagonist metoprolol against placebo on pulmonary function in 
asthmatic individuals. The interaction of these drugs with increasing doses of 
isoprenaline was also studied.65 
 
Both propranolol and metoprolol reduced FEV1 following their administration however 
the effect was more pronounced following propranolol. The effects of isoprenaline, a 
highly efficacious non-selective beta-agonist, was also completely blocked post 
propranolol however were similar to placebo following metoprolol. 
 
Following on from this Greefhorst, compared the relative deleterious effects of the 
relatively beta 1 selective atenolol, metoprolol and acebutolol.66 The three beta-blockers 
caused similar falls in exercise heart rate after two hours ingestion, indicating their 
equipotency. FEV1 fell by a significantly by a similar degree with each beta-blocker 
recovery occurring with the beta-2-agonist terbutaline. The degree of recovery with 
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acebutolol was less marked which the authors suggested may be due to the lower degree 
of beta-1 selectivity seen in comparison with the other two beta-blockers. 
 
At this time it was then clear the effects of bronchospasm seen with cardio-selective 
beta-blockers was less and the bronchodilator activity of beta-2-agonists could be 
preserved. Through these findings it was postulated that beta-1-adrenoceptor 
antagonists could potentially be used in asthmatics provided they were combined with 
beta-2-adrenoceptor agonists.66 
 
b. CASE REPORTS AND CONTRAINDICATIONS 
 
 
Concerns regarding beta-blocker use in asthma and COPD stems from previous case 
reports and safety of medicines registries.67-69 As increasing evidence emerged 
subsequent guidance from the Committee of Safety of Medicines in 1987 stated that 
beta-blockers whether selective or non-selective should not used in asthmatics due to 
associated risks of bronchospasm.  The Committee on Safety of Medicines reported that 
347 cases of bronchospasm and 25 deaths had been reported with beta-blockers with the 
majority of these events occurring in patients with asthma or obstructive airway 
disease.70 The concern regarding beta-blocker prescription remains to this day with a 
consensus statement from the European Society of Cardiology stating that, a history of 
asthma should be considered a contra-indication to the use of any beta-blocker.71  These 
guidelines are also routinely applied to patients with COPD. 
 
Historically case reports of severe asthma exacerbations and mortality have been 
reported with beta-blocker use. However it is unclear what severity of asthma these 
patients   had   and   it   could   be   argued   that   by   today’s   standards   these   individuals   were  
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poorly controlled.  Two case reports are routinely quoted as evidence for avoiding beta-
blockers in asthma.68,69 In both cases beta-blockers were given in high doses, in a non-
observed setting to asthmatics that would now be classed as poorly controlled.  It could 
be argued that based on the potential severity of asthma in these case reports, guidance 
advising a complete avoidance of beta-blockers in all patients with asthma or COPD 
was premature. 
 
There is more compelling evidence however of beta-blocker induced 
bronchoconstriction.      In  a  group  of  5  patients  classified  as  “asthmatic  bronchitics”  the  
degree of timolol eye drops induced bronchospasm was assessed.  In comparison with a 
group of healthy volunteers in whom there was no associated fall in FEV1 post timolol, 
a mean fall of 39% in FEV1 was seen (range 15% to 56%). This highlights the ability of 
timolol eye drops to be absorbed directly into the systemic circulation, bypassing first 
part metabolism and thus reaching the pulmonary circulation in significant 
concentrations to cause significant bronchoconstriction.72 
 
The concerns with timolol eye drops were reaffirmed when the National Registry of 
Drug-Induced Ocular Side Effects at Oregon University, USA reported 16 deaths 
following use of timolol eye drops in those with a predisposing history of asthma or 
COPD.73 
 
As a result of these case reports and registries underlining the concerns of use of beta-
blockers in asthmatic patients it became established to limit their use in both asthma and 
COPD patients thereby reducing any potential respiratory side effects from occurring 
(see table 2). 
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Reported Adverse Effects of Acute Beta-Blocker Prescription in Asthma 
x 1964: Mean fall of in FEV1 of 23% following 5-10mg of intravenous            
propranolol (n=10).61  
x 1965:  Mean fall of 9.1% in FEV1 following intravenous propranolol, mean 
dose 4.5%. (n=8).62 
x 1968: Mean fall of 44% in FEV1 following 5mg of intravenous propranolol. 
(n=9).64 
x 1975: Mean fall of 120ml in FEV1 following intravenous metoprolol 
(0.12mg/kg) and 200ml fall in FEV1 following intravenous propranolol 
(0.06mg/kg) (n=7).65 
x 1979: Two deaths reported with beta-blocker use in patients with airway 
obstruction (patient details, beta-blocker and dose not given).67 
x 1979: Mean fall in FEV1 of 26.5% following 100mg of oral propranolol 
(n=10) and 53.3% following 10mg of oral timolol (n=5).74 
x 1981: Mean fall of 350ml in FEV1 following atenolol (100mg), 360ml fall 
following metoprolol (100mg) and 270ml fall following acebutolol (400mg).66 
x 1981: Mean fall of 600ml in FEV1 following single dose of timolol eye drops 
(n=5).72 
x 1981: Near fatal bronchospasm reported following oral nadolol.68 
x 1984:Maximum fall in FEV1 of 17.6% following intravenous 
propranolol(n=6) (dose not given).75 
x 1984: 16 deaths reported following timolol eye drops use.73 
x 1987: 347 cases of bronchospasm with 25 deaths (reactions reported to both 
oral (n=299) and eye-drop preparations (n=48).70  
x 2001: Bronchospasm reported in 5 asthmatics (2 oral, 3 topical).76 
 
Table 2. Adverse Effects of Beta-Blocker in asthma 
 
c. EMERGING SAFETY DATA 
 
 
No clear distinction between the potential adverse effects of non-selective and cardio-
selective beta-blockers is made by clinical guidelines, with advice suggesting a 
complete avoidance of beta-blockers regardless of selectivity in asthma and COPD.71 
However limited data suggests that cardio-selective beta-blockers may be tolerated in 
patients   termed   to   have   “reactive   airway   disease” without any clear evidence of 
respiratory adverse effects.  In a meta-analysis by Salpeter, randomised placebo 
controlled trials, which studied the effects of cardio-selective beta-blockers in 
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predominantly patients with COPD were evaluated.77  In total 19 studies evaluating 
single dose treatment and 10 studies investigating chronic treatment (range 3 days to 4 
weeks) were included.  Within the meta-analysis administration of a single dose cardio-
selective beta-blocker was associated with a 7.46% (95%CI 5.59 to 9.32) reduction in 
FEV1.  This was in contrast with the non-significant fall in FEV1 of -0.42% (95%CI -
3.74 to 2.91) seen with chronic treatment.  Furthermore a smaller FEV1 response to 
beta-agonists was seen with acute treatment at 4.63% (95%CI 2.47 to 6.78) in 
comparison with chronic treatment of 8.74% (95%CI 1.96 to 15.52). 
 
With the absence of any worsening in symptoms following beta-blocker use 
demonstrated, this meta-analysis concluded that due to their potential beneficial effects 
in the treatment of cardiovascular disease, cardio-selective beta-blockers should not be 
withheld in individuals with mild to moderate reactive airway disease.77 
 
The conclusions from this meta-analysis have latterly been supported by a Cochrane 
review focusing on the effects of cardio-selective beta-blockers in COPD.78 Within the 
Cochrane review, 11 studies of single-dose treatment and 11 of treatment for longer 
durations, ranging from 2 days to 16 weeks, met selection criteria. Cardio-selective 
beta-blockers, given as a single dose or for longer duration, produced no change in 
FEV1 or respiratory symptoms compared to placebo, and did not affect the FEV1 
treatment response to beta-2-agonists.78 
Despite safety concerns, co-prescription of beta-blockers in asthma patients does occur, 
with a previous analysis of prescriptions issued in primary care in the Tayside region of 
Scotland demonstrating that 1.7% of patients receiving a beta-blocker prescription had 
received a beta-2-agonist in the preceding 30days.79  In an observational study by 
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Morales et al, the frequency of oral beta-blocker prescriptions in patients with asthma in 
general practice was recorded. The main outcome of the study was to determine whether 
beta-blocker prescriptions resulted in an increased prevalence of severe asthma 
exacerbations requiring oral steroids use.80 The incidence of oral beta-blocker 
prescriptions in patients with asthma was 6.4 per 1000 asthma patients per year with an 
annual prevalence of 2.2%. Furthermore the study found that the concerns of large 
increases in the number of patients prescribed rescue oral steroids did not occur 
following new oral beta-blocker therapy in active asthma. 
 
d. THE ROLE OF BETA-BLOCKERS IN HEART FAILURE 
 
 
Following the discovery of beta-blockers their benefits in the treatment of 
cardiovascular disease, immediately became apparent.  Propranolol itself was shown to 
have blood pressure lowering and anti-arrhythmic properties.81,82 With the development 
in the number of available beta-blockers came further evidence of their beneficial 
effects, with beta-blockade post myocardial infarction shown to reduce mortality.83,84 
 
Despite initial benefits being seen in the setting of hypertension and post myocardial 
infarction, acute dosing with beta-blockers in the setting of heart failure was avoided 
due to their reduction in cardiac contractility and increased risk of acute pulmonary 
oedema and short term adverse effects. 85 Conversely beta-agonists were routinely used 
due to their ability to improve myocardial contractility and cardiac output. However 
despite these acute benefits, chronic beta-agonist use in heart failure was associated 
with beta-receptor down-regulation and desensitization with ultimately increasing 
mortality.86,87 As a result of these concerns, beta-1-agonists, for example dobutamine 
are now only used in the acute management of heart failure in severely unwell 
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hospitalised patients.  This use of beta-agonists in the management of heart failure is 
intriguing due to the acute beneficial and chronic deleterious effects of beta agonist use 
in heart failure patients. 
 
Due to the potential acute deleterious effects it was widely accepted that beta-blockers 
should not be given to heart failure patients.88 In 1975 Waagstein et al, published work 
in congestive cardiomyopathy demonstrating a benefit with chronic beta-blockade.89 
This work represented a change in practice and thinking and would lead on to major 
multicentre trials including CIBIS-II,90 COPERNICUS91 and MERIT-HF92 all showing 
an approximate 1/3rd reduction in total mortality after chronic treatment with bisoprolol, 
carvediolol and extended release metoprolol succinate respectively. 
 
Thus the beneficial effects of chronic dosing overcame concerns of initial deterioration 
and possible fatal pulmonary oedema following acute beta-blocker use.  In order to 
avoid the potential for decompensating pulmonary oedema, chronic beta-blocker dosing 
is achieved by gradual dose titration. The evolution of beta-blocker use in heart failure 
from a contraindicated drug to routine use is intriguing. In fact the use of beta-blockers 
in heart failure has further evolved that to not give a beta-blocker to a heart failure 
patient without any contraindication could now be considered unethical. 
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3. THERAPEUTIC USE OF BETA-BLOCKERS IN 
ASTHMA 
a. THE BETA-BLOCKER HYPOTHESIS 
The observed effects of beta-blocker use in heart failure prompted investigators to 
evaluate the chronic dosing effects of beta-blockers in asthma.93  Based upon the 
differing acute and chronic effects of beta-antagonists in heart failure, whilst it was clear 
that acute beta-blockade in asthma was detrimental, the chronic effects of beta-blockade 
had not been examined.94  The concept for putative beneficial effects on airway hyper-
responsiveness with chronic beta-blockade in asthma may be plausible when it is 
considered that in asthma chronic exposure to beta-agonists causes beta-adrenoceptor 
down-regulation (reduction in receptor density and subsequent desensitisation) with 
associations to increasing exacerbations and loss of asthma control.  This is in contrast 
to chronic administration of beta-blockers in heart failure with subsequent receptor up-
regulation, with associated reductions in mortality (see table 3).95  
 
 
Prolonged treatment with an inverse agonist such as nadolol, carvediolol and 
propranolol, by reducing constitutive receptor activity, would permit the system to 
resensitize with subsequent up-regulation of beta-2-adrenoceptors. 96 The process by 
which beta-adrenoceptor up-regulation occurs with nadolol has previously been studied.  
In a study by Ohkuma et al, up-regulation of beta-adrenoceptors induced by nadolol is 
mediated by at least, two different processes, namely an increase in translocation of 
receptor proteins from cytosol to membrane with no changes in synthesis of receptor 
proteins and their mRNA and secondly increases in receptor protein synthesis with 
subsequent increased synthesis of their mRNA.97 In asthma it was hypothesised that this 
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beta-adrenoceptor up-regulation may translate into beneficial effects on airway hyper-
responsiveness. 
 
Beta-adrenoceptors : Acute vs. chronic therapy 
  Heart failure Asthma 
E-adrenergic 
receptor 
expression 
Acute 
Agonist Beneficial 
(↑contractility) 
Beneficial 
(bronchodilation) ↔ 
Antagonist Detrimental 
(↓contractility) 
Detrimental 
(bronchoconstriction) ↔ 
Chronic 
Agonist Detrimental 
(↑mortality) 
Detrimental? 
(↑AHR/Exac)* ↓ 
Antagonist Beneficial 
(↓mortality) 
Beneficial? 
(↓AHR) ↑ 
*AHR; airway hyper-responsiveness: Exac; exacerbation rate 
 
Table 3. Effects of acute and chronic beta-adrenoceptor agonism and antagonism. (Derived from 
Lipworth and Williamson)95 
 
 
b. MURINE MODELS 
Callaerts-Vegh et al published the first evidence suggesting potential putative benefits 
of chronic beta-blockade in asthma in 2004.98 In mice systemically sensitized to 
ovalbumin  in  order  to  simulate  an  “asthmatic  model”,  both  carvediol  and  nadolol  were  
found to reduce airway resistance to methacholine bronchial challenge agent and 
increase beta-adrenoceptor density following chronic 28 day dosing. These findings 
were in comparison with significant worsening in airway resistance to methacholine 
demonstrated after acute dosing. 98 
 
Both carvedilol and nadolol are examples of relatively non-selective beta-blockers with 
inverse agonist activity (i.e the ability to decrease receptor activity below basal level 
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and   essentially   “switches   off”   the   receptor), resulting in the authors concluding that 
beta-blockers with inverse agonist properties may exert reciprocating effects on cellular 
signaling dependent on duration of administration.98 
 
This study was followed by further data demonstrating an improvement in airway 
hyper-responsiveness and beta-2-adrenoceptor density in murine models of asthma 
following chronic administration of nadolol and ICI-118,551 (a highly beta-2-
adrenoceptor selective antagonist).  This was in contrast with the lack of significant 
improvements in AHR and adrenoceptor density following chronic metoprolol, a 
cardio-selective beta-blocker. 99 
 
In addition to beta-2-adrenoceptor up-regulation, chronic nadolol was associated with 
down regulation of phosphodiesterase 4D (PDE4D), which is normally associated with 
cAMP degradation and smooth muscle bronchoconstriction. Thereby providing 
evidence of a potential chronic bronchodilatory effect with nadolol.99 
 
Chronic nadolol and ICI-118,551 in murine models of asthma have been shown to have 
anti-inflammatory properties.  Chronic use for 28 days was associated with reductions 
in total cell counts, eosinophils, and the interleukins IL-13, IL-10, IL-5, and 
transforming growth factor beta-1 (TGF-b1) in bronchoalveolar lavage, and attenuated 
epithelial mucin content (see table 4).100   
 
Finally further evidence to support the potential role of beta-blockers in asthma can be 
derived from beta-2-adrenoceptor knockout mice. Being devoid of beta-2-adrenoceptors 
these murine models do not develop the asthmatic phenotype of mucous metaplasia, 
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increased AHR to bronchial challenge testing or inflammatory cells within bronchial 
alveolar lavage.101 
 
 
Chronic Effects of Nadolol in Murine Model of Asthma 
x Reduced AHR to methacholine.98,99 
x Increased beta-2-adrenoceptor density98,99 
x Decreased total inflammatory cells and eosinophils100 
x Decreased mucous metaplasia100 
x Decreased mucin production100 
x Decreased cytokines (Interleukins 5, 10, 13 and TGF-b1)100 
x Decreased expression of PDE4D99 
 
Table 4. Chronic effects of Nadolol in Murine Models of Asthma 
 
 
c. PILOT STUDIES 
In view of the potential putative effects of beta-blockers demonstrated in murine 
models, Hanania et al performed the first open label study of chronic non-selective beta-
blocker use in asthmatic patients in 2008.102 Performed in mild steroid naïve asthmatics 
with an FEV1 of >80% predicted, 10 participants underwent a dose titration of nadolol 
over a 6 week period with a further plateau period of 3 weeks once the maximum dose 
tolerated had been achieved. The maximum dose tolerated varied from 10mg (3 
participants), 20mg (4 participants) and 40mg (3 participants).  Notably of the 3 
participants that only managed to tolerate 10mg, 2 of these participants had significant 
falls in FEV1 that prevented further dose titration. 
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Although designed primarily as a safety study, the effect of chronic nadolol dosing on 
airway hyper-responsiveness was assessed. Of the 7 participants that tolerated 20mg or 
40mg of nadolol, there was a 1.8 doubling dilution shift in methacholine challenge 
following chronic dosing in comparison with baseline nadolol naïve measurements.  
This change is comparable with the improvements seen with inhaled corticosteroids.103 
Furthermore there was a dose dependent improvement in AHR was seen with chronic 
nadolol dosing (r=0.86, p=0.0016) with a 2.1 doubling dilution shift seen with 40mg of 
nadolol (p=0.0042). 
 
As expected following acute dosing with nadolol there was a significant fall in mean 
FEV1 of 7.4 % predicted. Following chronic nadolol dosing a significant fall in FEV1 
was observed with a mean change of 5% in comparison with baseline values (p<0.05).  
However it was noted that all participants were able to tolerate chronic nadolol dosing 
without any change in respiratory symptoms.  Systemic beta-blockade was suggested by 
a mean fall in heart rate of 7 beats per minute, however this change was not significant 
(p=0.051). 
 
The results of this study were intriguing given the disconnect seen by improvements in 
AHR with chronic nadolol dosing whilst worsening airway calibre was demonstrated by 
a significant albeit relatively small fall in FEV1. 
 
These findings were seen subsequently repeated in another study of 10 mild steroid 
naïve asthmatics performed by the same group, with a doubling dilution shift (SEM) of 
1.79 (0.44), p=0.004 seen following methacholine challenge with chronic nadolol 
dosing over a 13 week period.104 Interesting within this study 7 out of the 10 
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participants were able to tolerate the maximal dose of 40mg of nadolol. This is in 
comparison with 3 out of 10 participants in the first study102 and may be associated with 
the longer dose titration period of 10 weeks within this subsequent study.104 
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4. THERAPEUTIC USE OF BETA-BLOCKERS IN COPD 
 
a. MORBIDITY AND MORTALITY OF COPD 
Chronic obstructive pulmonary disease is associated with significant morbidity and 
mortality. Estimated to become the third leading cause of death worldwide by 2020, the 
presence of concurrent cardiovascular comorbidities within patients with Chronic 
Obstructive Pulmonary Disease (COPD) are increasingly becoming recognized as 
modifiable risk factors.105,106 Furthermore the presence of cardiovascular disease in 
COPD patients is significantly higher than the rates found in those without COPD. A 
pooled analysis of two large population-based epidemiological studies by Mannino et 
al, showed the prevalence of cardiovascular disease (defined as ischaemic heart disease, 
heart failure, stroke and/or transient ischaemic attack) in COPD patients was found to 
be 20–22% compared with 9% in subjects without COPD.107   
COPD and cardiovascular disease are undoubtedly linked due to smoking related 
atherosclerosis, however evidence suggests that despite this link the prevalence of 
cardiovascular disease is greater in COPD patients in comparison with matched 
smoking controls. In the “Evaluation of COPD Longitudinally to Identify Predictive 
Surrogate End-points: (ECLIPSE) study ECLIPSE  study,  ‘‘heart  trouble’’  was  reported  
in 26% of 2,164 COPD patients compared with 11% of 337 smoking controls 
(p=0.001).108  Patients with COPD frequently exacerbate with the risk of subsequent 
hospital admission independent to the severity of underlying pulmonary function.109 
Furthermore patients admitted with COPD exacerbations have an increased frequency 
of concurrent myocardial infarction.110 Therefore early identification of COPD patients 
at risk of developing cardiovascular disease is of great importance. With the exception 
of long term oxygen therapy, no therapeutic management in COPD has been associated 
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with a significant reduction in mortality.111,112 As a result the treatment of 
cardiovascular disease within COPD patients provides means of a potential method to 
improve long term outcome. 
b. OBSERVATIONAL STUDIES 
With the exception of highlighting the potential concerns with beta-blocker use, clinical 
guidelines do not differentiate the treatment of cardiovascular disease in COPD 
patients.58 Therefore unsurprisingly statins, angiotensin-converting enzymes inhibitors 
and angiotensin receptor blockers have all demonstrated beneficial effects in the 
treatment of cardiovascular disease in COPD populations.113 Beta-blockers have been 
associated with a reduction in mortality post-myocardial infarction and are now integral 
in the treatment of cardiovascular disease.114 The use of beta-blockers in COPD patients 
however remains controversial and subsequently they are under-utilised in COPD 
patients.115 However in addition to the emerging safety data regarding beta-blocker use, 
several observational studies have now focussed upon the use of beta-blockers in the 
COPD populations.78,116-118   
 
Potential benefits of beta-blocker use in COPD patients have been demonstrated in 
several observational studies.  Dransfield et al performed a retrospective study in 
patients admitted with an acute exacerbation of COPD as a primary diagnosis, those 
who with a history of beta-blocker treatment had reduced mortality OR 0.39 (95%CI 
0.15 to 0.99)).119 In patients who underwent major cardiovascular surgery, those with 
COPD who were treated with cardio-selective beta-blockers had a lower 30-day OR 
0.37 (95%CI 0.19 to 0.72) and long-term mortality HR 0.73 (95%CI 0.6 to 0.88) 
compared with those who did not receive this treatment.117 A recent study in the 
Netherlands using general practice electronic records, which included 2,230 patients 
  
51 
Netherlands using general practice electronic records, which included 2,230 patients 
with a diagnosis of COPD, also suggested that beta-blocker use was associated with 
decreased mortality HR 0.68 (95%CI 0.56 to 0.83) and exacerbation frequency HR 0.71 
(95%CI 0.60 to 0.83).116 Furthermore a recent meta-analysis has shown an overall 
beneficial effect on survival in COPD with the nine retrospective studies included 
resulting in a pooled relative risk of COPD related mortality secondary to beta-blocker 
use of 0.69 (95%CI 0.62 to 0.78) I2=82%.120 Although the potential beneficial effect of 
beta-blocker use in COPD is encouraging, at present no randomised controlled trial 
exists that examines the use of beta-blockers in COPD to either support of refute these 
findings. 
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5. SUMMARY AND THESIS OBJECTIVES 
 
Beta-blockers are avoided in asthma and COPD due to concerns of drug induced 
bronchospasm. This thesis evaluates the use of beta-blockers in asthma and COPD by 
means of both randomised controlled trials and observational studies. 
 
a. PROOF OF CONCEPT STUDIES IN ASTHMA 
Two randomised controlled trials are included in this thesis. These studies address the 
safety of acute dosing of both cardio-selective and non-selective beta-blockers and the 
chronic dosing effects of non-selective beta-blockade. 
 
Patients’ safety is paramount when conducting clinical trials with beta-blockers in 
asthma. Therefore firstly a study was designed to assess the effects of acute dosing of 
the non-selective beta-blocker, propranolol. The aim of the study was to establish 
whether ingestion of a single dose of oral propranolol would prevent subsequent 
salbutamol and ipratropium recovery, following histamine challenge to mimic acute 
bronchoconstriction present during an asthma exacerbation. The results of this study are 
discussed in chapter 3. Within the acute doing study, a novel method of assessing 
airway calibre, namely impulse oscillometry (IOS) was used in addition to standardised 
spirometry.  In a post-hoc analysis of the acute dosing study the relative sensitivities of 
IOS and spirometry were compared in the assessment of bronchoconstriction to 
propranolol and bronchodilatation to salbutamol.  The results of this analysis are 
discussed in chapter 4. 
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The second randomised controlled trial included in this thesis, evaluates the effects of 
chronic dosing with propranolol in mild-to-moderate asthmatics controlled on inhaled 
corticosteroids.  The aim of this study was to assess whether the putative beneficial 
effects of non-selective beta-blockade on airway hyper-responsiveness, previously 
demonstrated in open label studies could be reproduced in a placebo controlled trial in 
asthmatics controlled on inhaled corticosteroids.102,104 Furthermore the safety profile of 
chronic beta-blocker dosing in asthma was assessed.  The results of this study are 
discussed in chapter 5.  Within the chronic dosing study, prior to randomisation to 
propranolol or placebo, a safety visit where participants received an intravenous dose of 
the cardio-selective beta-blocker, esmolol was performed. The results of this subgroup 
analysis are discussed in chapter 6. 
 
 
b. OBSERVATIONAL STUDY IN CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE 
 
Previous studies have suggested a potential survival benefit with beta-blocker use in 
COPD.116,120 These studies have however failed to assess the interaction of beta-
blockers with beta-agonists given the theoretical interactions or the interaction with 
other inhaled bronchodilators. In order to address this an observational study of a 
National Health Service (NHS) database of COPD patients was performed. This study 
evaluated the impact of beta-blocker use on mortality, hospital admissions and 
exacerbations when added to established stepwise inhaled therapy for COPD. The 
results of this study are discussed in chapter 7. 
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CHAPTER 2: 
 METHODS 
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1. RANDOMISED CONTROLLED TRIALS 
Detailed protocols for each analysis will be described in chapters 3 to 6, however many 
aspects of the methodology are common to all studies, and are therefore are described 
here. 
a. ASTHMA SUBJECT SELECTION 
Asthmatic subjects were recruited from the Asthma and Allergy Research Group 
database. This database includes individuals who have agreed to be contacted with 
regards to participating in clinical research within the department.  Potentially suitable 
participants were contacted by telephone or post and invited to participate based upon 
their baseline demographic data held within the database including age, onset of asthma 
symptoms, lung function, symptom scores, treatment and airway hyper-responsiveness. 
Further subjects were recruited by the use of local advertising: posters in the hospital 
and advertisements in local press.  Potential participants received a written participant 
information sheet detailing the individual study requirements and the extent of their 
participation before attending the department for a screening visit. All patients who 
entered the studies had a clinical diagnosis of asthma as defined by current 
guidelines.121 
All participants were between 18 and 65 years of age. Participants were required to have 
a normal screening examination, comprising physical examination, urinalysis, and 
haematology and biochemical screening prior to enrollment.  All participants were 
consented by the principal investigator or appropriate research team member who had 
the appropriate good clinical practice (GCP) training and was named on the delegation 
log. 
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All study protocols and subject information sheets were approved by the Tayside 
Committee on Medical Research Ethics. All study materials where appropriate were 
approved by the Medicines and Healthcare Products Regulatory Authority. 
b. SPIROMETRY 
 
Spirometry was performed in accordance with the published American Thoracic Society 
guidelines.122 Participants were asked to breathe in to total lung capacity and then 
exhale forcibly to residual volume. This manoeuvre allowed calculation of FEV1 (forced 
expiratory volume in 1 second), FEF25-75 (forced expiratory flow within 25% and 75% 
of forced vital capacity) and FVC (forced vital capacity).  All measurements were 
carried out in triplicate. The highest of 3 values for FEV1, repeatable within 5% was 
recorded and the percentage predicted (according to sex, ethnicity, height and weight) 
was calculated. A Micro Medical SuperSpiro (Micro Medical Ltd, Rochester, United 
Kingdom) was used for all studies. 
 
c. IMPULSE OSCILLOMETRY 
 
Impulse oscillometry (IOS) was performed in accordance with published guidelines.123 
IOS is an effort independent method of assessing airway resistance by the use of small 
amplitude sound waves being superimposed on normal breathing cycles.  Participants 
supported their cheeks to reduce shunting, whilst impulses were applied during 30 
seconds of tidal breathing. This manoeuvre allows airway resistance and reactance to be 
determined.  All measurements were performed in triplicate and means taken.  A Jaeger 
Masterscreen Impulse Oscillometer (Erich Jaeger, Hoechberg, Germany) was used for 
all studies. 
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d. BRONCHIAL CHALLENGE TESTING 
 
Airway hyper-responsiveness is usually defined as an increase in sensitivity to a wide 
variety of airway narrowing stimuli. Both methacholine and histamine bronchial 
challenge tests are used to measure airway hyper-responsiveness (AHR) in asthma. 
However airway hyper-responsiveness is a composite of airway hypersensitivity to the 
inhaled stimulus and the associated reduction in airway calibre observed.   Within this 
thesis a 20% fall in FEV1 following less than or equal to 8mg/ml of methacholine or 
histamine is considered evidence of increased AHR.    
 
Methacholine was made up into doubling dilutions with concentrations ranging between 
0.03 to 32mg/ml.  Histamine was made up into doubling dilutions with concentrations 
ranging from 0.3125 to 40mg/ml. Solutions were prepared by Tayside Pharmaceuticals 
(Ninewells Hospital, Dundee) using the diluent benzyl alcohol.  Bronchial challenge 
testing was performed according to recommended guidelines using a validated computer 
assisted dosimetric method.124,125 A baseline FEV1 measurement was taken prior to each 
challenge test to ensure participant safety. Participants with an FEV1 less than 60% 
predicted were excluded from challenge testing as per American thoracic society 
guidelines.125 A further FEV1 was taken following taken following administration of the 
diluent (benzyl alcohol) alone. This recording was used to derive the subsequent %fall 
in FEV1 post methacholine or histamine respectively. Methacholine or histamine were 
then administered in doubling cumulative doses until a 20% fall from the post-diluent 
measurement was achieved.  The PC20 values were calculated by computer-assisted 
logarithmic interpolation of the dose response curve.126 
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Whilst the PC20 value is generally accepted as the standardised measurement of airway 
hyper-responsiveness, the slope of the dose response curve has also been suggested as 
providing valuable information when determining airway hyper-responsiveness.  When 
analysing the shape of the dose response curve to either methacholine or histamine, 
dose-response curves in asthmatic patients have a steeper slope and a higher maximal 
response at high doses as compared to normal controls.  It has therefore been suggested 
that the term bronchial "reactivity" designated the slope of the curve, as opposed to 
bronchial "sensitivity" indicating the position (PC20).127  For the purpose of this thesis, 
PC20 was measured rather than the slope of the curve due to objective nature of this 
measurement. 
e. EXHALED NITRIC OXIDE 
 
Exhaled nitric oxide, a surrogate marker of airway inflammation was recorded using a 
portable device (NIOX MINO® Airway Inflammation Monitor; Aerocrine AB, Solna, 
Sweden). All measurements were made prior to measurement of spirometry to ensure 
accuracy of results. A sustained plateau of at least 8 seconds with a mouth flow rate of 
50 ml/s and a pressure of 10 cm H2O were used. The arithmetic mean was derived 
according to the current American Thoracic Society recommendations.128 
f. PERIPHERAL BLOOD MEASUREMENTS 
 
A 5ml blood sample for Full Blood count and a separate 3ml blood sample for 
measurement of Urea and Electrolytes and Liver Function were taken at respective 
study screening visits. Within the acute dosing study serial 3ml samples were taken for 
measurement of serum potassium. All blood samples were processed by the 
biochemistry department of NHS Tayside, Ninewells Hospital Dundee. 
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g. QUALITY OF LIFE MEASUREMENTS 
 
The Mini Juniper Asthma Quality of Life Questionnaire (Mini-AQLQ) and Asthma 
Control Questionnaire (ACQ) were used.  These questionnaires have been validated and 
have been shown to be sensitive markers of asthma control and quality of life.129,130  
The Mini-AQLQ has a total of fifteen questions; each question has a response score 
ranging from zero to seven. The questions are grouped into four domains; activity 
limitations, symptoms, emotions and exposure. The Asthma Control Questionnaire has 
seven questions, five of which are based on symptoms with the remaining two based on 
FEV1 and rescue bronchodilator use. The five symptom questions have seven responses. 
A score of 0.75 indicates well controlled asthma, where as a score of 1.25 indicates 
poorly controlled asthma.130 The minimally important difference for both questionnaires 
is 0.5 units.131  
 
h. DOMICILLIARY LUNG FUNCTION MEASURMENTS 
 
Domiciliary FEV1 and peak expiratory flow were recorded in triplicate both morning 
and evening using an electronic handheld PiKo monitor (n-Spire Health, Longmont, 
Collorado,  USA)  according  to  manufacturer’s  instructions.132 
 
i. SYSTEMIC MEAUREMENTS OF BETA-1 AND  
BETA-2- ADRENERGIC RESPONSE 
Serum potassium was measured within this thesis as a marker of systemic beta-2-
adrenergic response.  Within chapter 3, measurement of serum potassium was used to 
determine the presence or absence of systemic beta-blockade following acute 
propranolol dosing.  As previously described competitive inhibition of the beta-2-
adrenoceptor by beta-blockade decreases Na-K-ATPase function and reduces potassium 
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uptake by cells, thereby resulting in increases in serum potassium.31 Alternative 
measurements of systemic beta-adrenoceptor activity include measurement of beta-
agonist induced tremor.   Previous work in this department has assessed the relevance of 
these surrogate markers for assessing beta-2-adrenergic activity. When assessing the 
response to salbutamol, plasma concentrations of salbutamol are significantly correlated 
to both changes in plasma potassium (Cmax r=0.904; Cav r=0.899) and tremor (Cmax 
r=0.875; Cav r=0.857).133  These results highlight the suitability of both surrogate 
markers of systemic beta-adrenoceptor activity. However due to the complexity of the 
study visits within the study described within chapter 3, serum potassium was regarded 
as more practically achievable marker in comparison with measurement of beta-agonist 
induced tremor.  
 
Within chapter 5, resting heart rate and salbutamol induced chronotropic response were 
used as markers of systemic beta-blockade. These markers were chosen due to the 
nature of study visits. However when assessing systemic beta-blockade exercise 
induced chronotropic incompetence is potentially a more effective marker in 
comparison with measurement of resting heart rate and salbutamol induced 
tachycardia.134 
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2. OBSERVATIONAL COHORT STUDY 
 
Detailed methodology with regards to the COPD Observational study included in this 
thesis is included in chapter 7. An overview of the COPD subject selection and the 
health informatics infrastructure required for the analysis are discussed here. 
 
a. COPD SUBJECT SELECTION 
 
Since its inception in 2001, the Tayside Respiratory Disease Information System 
(TARDIS) has enrolled patients with COPD into a structured management programme 
to support primary care practitioners and secondary care respiratory physicians in 
managing patients with COPD in Tayside, Scotland.  Patients attend annual review 
visits where data including lung function, symptoms and exercise tolerance are 
collected.  TARDIS thereby provides an unselected disease specific dataset, which has 
previously been used in observational studies in COPD.135 Only patients with complete 
datasets and aged over 50 years at the time entry into TARDIS were included in the 
study described in chapter 7. 
 
b. HEALTH INFORMATICS 
 
The Health Informatics Centre (HIC) at the University of Dundee, provides a resource 
whereby several independent clinical datasets can be linked by a common patient 
identifier. The combined dataset generated is then anonymised and provided to the 
researcher.  Clinical datasets provided by HIC included hospital admission data using 
Scottish morbidity records (SMR), prescription data from the Tayside Community 
Prescription database and death records from the General Register Office for Scotland. 
For this study each dataset was combined the TARDIS dataset, thereby providing a 
COPD specific dataset with outcome data including mortality, hospital admissions and 
COPD exacerbations (figure 5). 
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Figure 5. Flow diagram of Health Informatics Centre datasets 
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CHAPTER 3: 
 
RANDOMISED PLACEBO 
CONTROLLED TRIAL 
ASSESSING THE EFFECTS OF 
HYDROCORTISONE ON 
ACUTE NON-SELECTIVE 
BETA-BLOCKER AND 
HISTAMINE INDUCED 
BRONCHOCONSTRICTION 
 
 
Study Aims: 
1. To assess for the presence of bronchoconstriction following acute dosing 
with oral propranolol in mild-to-moderate asthmatics. 
2. To establish whether acute propranolol dosing would prevent subsequent 
salbutamol and ipratropium recovery, following histamine challenge to 
mimic acute bronchoconstriction present during an asthma exacerbation. 
3. To determine if acute administration of intravenous hydrocortisone might 
partially obviate the effects of acute beta-2-blockade and improve the 
effects of nebulised salbutamol. 
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1. INTRODUCTION 
 
Beta-blocker induced bronchoconstriction is most pronounced following the first dose 
with non-selective drugs due to beta-2-adrenoceptor antagonism.  First shown by 
McNeill, in a group of 10 asthmatic patients, the mean fall in FEV1 was 23% (range 6% 
to 56%) following 5-10mg of intravenous propranolol.61 
 
Concern regarding beta-blocker use in asthma increased throughout the 1980s with case 
reports and guidance stating that beta-blockers regardless of selectivity, should not used 
in asthmatics due to risk of bronchospasm. 68-70 However when applied to larger 
asthmatic study populations, co-prescription of beta-blockers and beta-agonists has been 
reported.79,136 
 
A meta-analysis has examined cardio-selective beta-blockers use in reactive airways 
disease.  Although FEV1 mean fall was 7.5% following single dosing, no significant fall 
was seen with chronic dosing.77 This disconnect between acute and chronic effects, 
mirrors the response seen to beta-blocker use in heart failure.  Once contraindicated due 
to concerns following acute dosing, beta-blockers are now established as a main chronic 
treatment choice for heart failure.91 
 
With these reassurances, studies have begun to explore the potential therapeutic benefits 
of chronic beta-blockade in asthma.  The non-selective beta-blocker, nadolol has been 
shown to reduce airway hyper-responsiveness (AHR) and inflammation and may lead to 
up-regulation of beta-2-receptors in murine models.98,99,101 This led to two open-pilot 
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studies in steroid naïve asthmatics, with chronic nadolol dosing achieving significant 
improvements in AHR.102,104 
 
Patients’   safety   is   paramount  when   conducting   clinical   trials  with   non-selective beta-
blockers in asthma.137 Although salbutamol reversibility has been shown to be 
preserved following chronic beta-blockade with the non-selective beta-blocker 
nadolol,104 concerns remain during the early period of beta-blocker exposure, primarily 
following the first dose, before any disease modifying activity has occurred. Previous 
studies have identified it takes approximately 2 weeks for beta-2-adrenoceptor up-
regulation to occur, suggesting this would be the theoretical at risk period during up 
titration with beta-blockade in asthmatics.138,139 
 
This study aimed to establish whether ingestion of a single dose of the non selective 
beta-blocker, propranolol would prevent subsequent salbutamol and ipratropium 
recovery, following histamine challenge to mimic acute bronchoconstriction present 
during an asthma exacerbation. Furthermore this study aimed to determine if acute 
administration of intravenous hydrocortisone might partially obviate the effects of acute 
beta-2-blockade and improve the effects of nebulised salbutamol due its acute 
facilitatory effects on beta-2-receptors within 3 hours of administration.47 
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2. METHODS 
Study Subjects 
Persistent atopic asthmatics, FEV1 >80% predicted,   taking   ≤1000µg   beclomethasone 
dipropionate (BDP) dose equivalent of inhaled corticosteroids (ICS), aged 18-65yr who 
had AHR to histamine challenge were recruited.  All participants were non-smokers.  
Exclusions included resting systolic blood pressure (BP) <100mmHg and heart rate 
(HR) <60beats-per-minute, history of arrhythmias, diabetes or rate limiting medications. 
Subjects were invited to participate from a list of known volunteers who had expressed 
an interest to take part in clinical trials within our department.  Potential participants 
received a written participant information sheet detailing the trial requirements and the 
extent of their participation before attending for a screening visit.  
 
Study Design 
A double-blind randomised placebo controlled crossover study was performed, 
consisting of an average of 3 (maximum 4) separate laboratory study visits over 3 
weeks (see figure 6).   The Tayside Medical Research Ethics Committee gave approval 
before commencement of the trial. The study was registered with www.clinicaltrials.gov 
(NCT 01070225).  Blinding and randomisation of treatment limbs was performed by the 
Clinical Trials Pharmacy, University of Dundee. 
 
At screening, spirometry, impulse oscillometry (IOS) and histamine bronchial challenge 
were performed. Participants were issued a peak flow meter (PEF) meter and continued 
on their regular ICS dose. Long Acting-Beta-Agonist (LABA) therapy was stopped 
during the study. Combination ICS/LABA was switched to ICS alone. Ipratopium was 
used a first line reliever therapy with salbutamol restricted to second line if required. 
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One week post screening visit, participants underwent their first 6 hour laboratory study 
visit.  Following baseline spirometry and IOS, domiciliary PEF was analysed to ensure 
<20% diurnal variation.  Participants ingested 10mg propranolol tablet.  Spirometry, 
IOS, BP and HR were observed. At 2 hours, if fell FEV1≥   10%   the   study   visit  
continued. If FEV1 fell <10%, the study visit ended and was repeated on a separate day 
using 20mg of propranolol. 
 
Two hours post-propranolol (10mg or when required 20mg), participants were 
randomised to receive 400mg of intravenous hydrocortisone or placebo (0.9% NaCl). At 
4 hours post-propranolol, participants underwent histamine challenge (PC10) with 
reversibility to sequential salbutamol 5mg and ipratropium 500mcg nebulisers. 
Spirometry and IOS were performed 20 minutes post salbutamol and ipratropium.  
Serum potassium was measured at baseline, 2, and 4 hours post-propranolol, 20 minutes 
post salbutamol. A final study visit was performed where treatment limbs were crossed-
over (duration between visits 3-5 days).  The participant received either intravenous 
hydrocortisone or placebo (0.9% NaCl) depending on their initial randomisation. At all 
study visits, the investigator was blinded to the treatment given (hydrocortisone or 
placebo). The same dose of propranolol was used and the visit was repeated as outlined 
above. 
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Measurements 
 
Spirometry was performed in accordance with published guidelines.122  Impulse 
oscillometry (IOS) was also performed as an alternative measure of assessing lung 
function.  IOS is an effort independent method of assessing airway resistance by the use 
of small amplitude sound waves being superimposed on normal breathing cycles and 
was performed in accordance with published guidelines.123 The airway resistance at 5 
Hz (R5) was recorded. A SuperSpiro spirometer (Micro Medical, UK) and IOS Jaeger 
Masterscreen (Germany) were used. Histamine Bronchial Challenge (PC10) was 
performed. A Mefar dosimeter was used with doubling concentrations from 0.3125-to-
40mg/ml. The provocative concentration of histamine required to cause a 10% and not 
the standard 20% fall in FEV1 was calculated (PC10) in view of safety. We did not use 
methacholine challenge as this would be directly antagonised by ipratropium. For the 
purpose of this study, atopy was defined as having a history of one or more positive skin 
prick tests to common allergens (grasses, trees, weeds, house dust mites, aspergillus, 
feathers, dog and cat). 
 
Analysis 
Data was analysed for normality with Shapiro-Wilk tests and Boxplots. The primary 
analysis was the difference in salbutamol recovery for hydrocortisone versus placebo. 
Recovery was determined as change in FEV1 (ml) post-salbutamol from lowest post 
histamine FEV1. A priori calculation predicted 13 patients would have an 80% power to 
detect a difference of 200ml between recovery FEV1 with a 2-sided significance level of 
0.05, assuming a within-patient standard deviation of 150ml. Salbutamol recovery was 
also assessed by change in FEV1% predicted, R5 and R5% predicted. Secondary 
69 
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analysis included assessment of beta-blocker induced bronchoconstriction, the effects of 
beta-blockade on staged salbutamol and ipratropium reversibility post histamine 
challenge, and evidence of systemic beta-blockade (serum potassium, HR, BP).  
Analysis of variance of repeated measures was performed with Bonferroni-correction 
for pair-wise   comparisons   with   a   two   tailed   α-error set at 0.05.   All analyses were 
performed on a per-protocol basis using SPSS version 17 (SPSS Inc, Chicago, IL). 
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3. RESULTS 
Of 26 participants screened, 15 participants were randomised. A total of 13 participants 
(7 male, 6 female) completed the study (see figure 7). Mean age (SEM) was 34 (3). 2 
participants withdrew as they could not complete the study visits for personal reasons. 
11 participants had less than a 10% fall in FEV1 after 10mg of propranolol and 
subsequently were given 20mg. There were no adverse events following beta-blocker 
ingestion (see table 5). 
 
 
Figure 7. Study consort diagram
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 Comparison between study visits. 
There was no significant difference between the histamine PC10 mg/ml on study visits 
(hydrocortisone and placebo) and the screening visit. 
 
Effect of hydrocortisone on nebulised salbutamol post sequential beta-blockade and 
histamine challenge. 
There was no significance difference in salbutamol recovery measured by change in 
FEV1 (ml) post histamine challenge following intravenous hydrocortisone verses 
placebo (mean difference 0.04 (95%CI -0.07 to 0.15), p=0.417).  There was also no 
change when comparing FEV1% predicted (mean difference 6.6 (95%CI -5.9 to 19.1), 
p=0.263), R5 (kPa l-1s) (mean difference 0.03  (95%CI -0.03 to 0.08), p=0.274) and 
R5% predicted (mean difference 10.9 (95%CI -9.0 to 30.9), p=0.255). Therefore 
intravenous hydrocortisone did not potentiate the effect of salbutamol recovery post 
sequential beta-blockade and histamine challenge. 
 
Analysis of beta-blocker induced bronchoconstriction 
For the hydrocortisone visit there was a fall in FEV1% predicted 2 hours post-
propranolol of 3.8% (95%CI -0.9 to 8.5), p=0.083, whilst at the placebo visit a 
significant fall of 4.7% was observed (95%CI 1.8 to 7.5), p=0.008. No significant falls 
in FEV1% were observed at 4 hours post-propranolol on either visit (see table 5, figure 
8). There was a significant increase in R5% predicted at 2 and 4 hours post propranolol 
on both visits, with a mean increase of 31.3% on the placebo visit at 2 hours (95%CI   
15.6 to 47.0), p=0.04. (see table 6, figure 8). 
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 Outcome I.V Hydocortisone 
Visit  
 (Mean, SEM) 
Placebo (I.V 0.9% 
NaCl)  
Visit 
 (Mean, SEM) 
FEV1 % predicted 
Baseline (t=0mins) 
2 hours post Propranolol (t=120 mins) 
2 hours post i.v Hydrocortisone or Saline (t=240mins) 
Post Histamine Challenge PC10 (t=250 mins) 
20mins Post Salbutamol (t=270 mins) 
20 mins Post Ipratropium Bromide (t= 290 mins)                                   
 
95.4 (2.8) 
91.6 (3.2) 
92.6 (2.8) 
78.0 (3.4)** 
99.2 (2.6) 
103.9 (2.8)* 
 
97.4 (2.6) 
92.7 (2.9)* 
94.8 (2.9) 
78.3 (3.9)** 
100.3 (2.6) 
104.4 (2.9)* 
R5 % predicted  
Baseline (t=0mins) 
2 hours post Propranolol (t=120 mins) 
2 hours post i.v Hydrocortisone or Saline (t=240mins) 
Post Histamine Challenge PC10 (t=250 mins) 
20mins Post Salbutamol (t=270 mins) 
20 mins Post Ipratropium Bromide (t= 290 mins)                                                                    
 
123.3 (10.5) 
149.0 (12.35)* 
144.8 (10.36)* 
183.3 (11.6)** 
99.6 (5.1) 
98.1 (4.9)
 
113.7 (6.3) 
145.0 (11.4)* 
136.8 (8.6)* 
192.3 (16.9)** 
97.7 (4.9)* 
90.6 (4.6)* 
 
 
Table 6.  FEV1% and R5% throughout study visits 
 
Data displayed as Mean (SEM). 
*Significant difference between time point and baseline , p<0.05 
**Significant difference between time point and baseline, p<0.001 
Significance calculated by ANOVA of repeated measures with post-hoc bonferroni correction. 
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Systemic beta-1 and beta-2-blockade 
Heart rate was significantly lower 2 hours post-propranolol at the hydrocortisone (mean 
change 20bpm, (95%CI 14 to 27), p<0.001 and placebo visits (mean change 16bpm 
(95%CI 13 to 20), p<0.001.  No significant changes were observed with blood pressure 
post propranolol ingestion. Serum potassium levels were significantly increased at 4 
hours post-propranolol on both visits, and did not reverse back to baseline following 
salbutamol recovery (see figure 8). Thus showing evidence of sustained beta-2-receptor 
blockade throughout the study. 
 
Reversibility post sequential beta-blockade and histamine challenge 
On both visits all spirometry (FEV1, FVC) and IOS measurements R5 (total airway 
resistance), R20 (central airway resistance), R5-R20 (peripheral airway resistance), X5 
(lung reactance) either returned back to baseline values or significantly improved in 
comparison with baseline after nebulised salbutamol, with only small further 
improvements seen following ipratropium (see figure 8, tables 6-8). 
 
Reliever Use 
Throughout the study visits, on requirement of reliever therapy, participants were 
administered ipratropium bromide in preference to salbutamol.  Salbutamol was 
however used if ipratropium was deemed to be ineffective. No participant required 
salbutamol to be administered during study visits. Furthermore there was no significant 
greater use of ipratropium throughout the study in comparison with normal reliever 
requirements (p> 0.05).  
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Table 8. Spirometry (FEV1, FVC, FEF25-75) throughout study visits 
 
Data displayed as Mean (SEM). * p <0.05 compared with Baseline, ** p<0.01 compared with Baseline, 
*** p <0.001 compared with Baseline.  Significance calculated by ANOVA of repeated measures with 
post-hoc bonferroni corrections 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time Point 
Outcome 
FEV1 (L) FVC (L) FEF25-75 (L) 
Hydrocortiso
ne Limb 
Saline         
Limb 
Hydrocortisone 
Limb 
Saline  
Limb        
Hydrocortisone 
Limb 
Saline  
Limb        
Baseline  
(t=0 mins) 3.23 (0.18) 
 
3.3 0 (0.19) 
 
4.19 (0.22) 
 
4.20 (0.23) 
 
2.68 (0.21) 
 
2.80 (0.22) 
2 hours post 
Propranolol 
 (t=120 mins) 3.10 (0.18) 
 
 
3.14 (0.18)* 
 
 
4.00 (0.19) 
 
 
4.05 (0.23) 
 
 
2.56 (0.23) 
 
 
2.59 (0.18) 
2 hours post i.v 
Hydrocortisone 
or Saline  
(t=240 mins) 
 
3.14 (0.18) 
 
3.20 (0.17) 
 
 
 
4.02 (0.21) 
 
 
 
4.10 (0.22) 
 
 
 
2.59 (0.18) 
 
 
2.70 (0.19) 
 
Post Histamine 
Challenge PC10 
(t=250 mins) 
2.64 
(0.16)*** 
 
 
2.62 (0.15)** 
 
 
3.57 (0.22)** 
 
3.60 (0.22)** 
 
 
2.05 (0.14)** 
 
 
2.01 (0.14)** 
 
20mins Post 
Salbutamol 
 (t=270 mins) 3.37 (0.19) 
 
 
3.39 (0.17) 
 
 
4.14 (0.22) 
 
 
4.30 (0.18) 
 
 
3.10 (0.14) 
 
 
3.10 (0.24) 
20 mins Post 
Ipratropium 
Bromide  
(t=290 mins)                                   
3.51 (0.18)** 
 
3.52 (0.18)** 
 
 
 
4.24 (0.19) 
 
 
4.27 (0.20) 
 
 
3.39 (0.26)** 
 
 
3.42 (0.25)** 
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4. DISCUSSION 
The major issue when conducting clinical trials using beta-blockers in asthma is patient 
safety. Whilst salbutamol has been shown to reverse bronchial challenge induced 
bronchoconstriction following chronic beta-blockade, this has not been reported 
following acute beta-blockade.104 This study has demonstrated that nebulised 
salbutamol is able to reverse sequential single dose propranolol and histamine induced 
bronchoconstriction in this study cohort. 
 
The primary study endpoint was to assess if acute administration of intravenous 
hydrocortisone might partially obviate the effects of acute beta-2-blockade and improve 
the effects of nebulised salbutamol.  Subsensitivity of beta-2-adrenoceptors occurs 
following treatment with long acting beta-agonists.42,140 Previous work has shown that 
high dose systemic corticosteroids (200mg intravenous hydrocortisone with 50mg oral 
prednisolone) can re-establish the beta-2-adrenoceptor function following agonist 
promoted down-regulation.47 These effects were seen in patients already taking inhaled 
corticosteroids with a median dose of 1000ug/day budesonide, thus suggesting that 
systemic corticosteroid has a dual action in acute asthma, with effects on beta-2-
adrenoceptor response as well as established ant-inflammatory properties. It therefore 
seemed plausible in this instance that a similar response may occur with intravenous 
corticosteroid following acute beta-blockade (ie. reversal of beta-blockade whilst re-
establishing beta-agonist sensitivity). 
 
This study showed that intravenous hydrocortisone did not potentiate the effect of 
salbutamol on FEV1 recovery post sequential beta-blockade and histamine challenge.  It 
is worth pointing out though, that even in the placebo arm salbutamol reversed 
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histamine induced bronchoconstriction back to baseline, therefore there may have been 
no further room for improvement with intravenous corticosteroid.  Moreover as LABAs 
were withdrawn for the duration of the study, there was no agonist promoted down-
regulation, aside from the effects of on demand salbutamol in between study visits.  
However in a real life scenario of a patient having an asthma exacerbation whilst 
concurrently receiving beta-blockers, it would still be prudent to give acute systemic 
corticosteroid to treat any worsening airway inflammation, as well as reversing any 
down-regulation due to concomitant LABAs. This study did not address the potential 
influence of acute corticosteroids on airway inflammation, because histamine works 
directly on airway smooth muscle histamine receptors to produce bronchoconstriction. 
 
This study evaluated the relative sensitivity of spirometry and impulse oscillometry at 
demonstrating the effects of beta-blocker induced bronchoconstriction. Due to safety 
concerns, and to mimic the proposed initial dose for a future chronic dosing study, low 
doses of propranolol were used in this study. Despite participants having relatively 
preserved spirometry, indicating mild-to-moderate disease, all participants received 
inhaled corticosteroids for asthma control. In the selected cases where the baseline 
histamine PC10 was greater than 8mg/ml, these patients all received at least 800ug/day 
BDP.  It can be presumed that reducing inhaled corticosteroids would result in a 
worsening of response to histamine bronchial provocation, however the histamine PC10 
threshold was irrelevant in this study, with the pertinent inclusion criteria being that 
each patient experienced a 10% fall in FEV1 post histamine challenge, thus allowing us 
to assess reversibility to salbutamol and ipratropium in the presence of acute beta-
blockade. 
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In view of relatively preserved spirometry in the study subjects, IOS was used to assess 
airway resistance. IOS has been shown to be a more sensitive marker of bronchodilation 
than spirometry in mild asthmatics receiving salbutamol, and thus it was hypothesised 
that IOS would be more sensitive at identifying any evidence of beta-blocker induced 
bronchoconstriction.141 This proved to be the case with FEV1% predicted falling by 
4.7% on the placebo visit at 2hours post-propranolol with R5% predicted, (a measure of 
total airway resistance) increasing by 31.3% post propranolol at the same time point and 
visit. R5% predicted also significantly increased 25.7% on the hydrocortisone visit at 2 
hours post-propranolol whilst FEV1% did not fall significantly 2 hours post-propranolol.  
The difference in change in FEV1% 2 hours post-propranolol between the 
hydrocortisone and placebo visit, highlights that in patients with preserved lung 
function, IOS is a more sensitive method of assessing bronchoconstriction and the 
discordance in FEV1 between visits may be partly due to daily FEV1 variability.  
Furthermore airway resistance measured by R5, R20 and R5-R20 all showed persistent 
significant deterioration at 4hours post-propranolol, whilst spirometry measures no 
longer demonstrated any evidence of bronchoconstriction at the same time point (prior 
to histamine challenge). 
 
Heart rate and serum potassium measurements provided surrogate markers of systemic 
beta-1 and beta-2 adrenoceptor blockade respectively.142  Serum potassium remained 
significantly elevated following ingestion of propranolol and failed reverse back to 
baseline following high dose salbutamol.  This provided evidence of sustained systemic 
beta-2-blockade throughout the study period and supports previous work showing a 
prevention of salbutamol-induced hypokaleamia in the presence of propranolol 40mg as 
a single dose.143 
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This study has therefore demonstrated an unexpected disconnect between the interaction 
of propranolol and salbutamol on airway smooth muscle and skeletal muscle beta-2-
adrenoceptors.  Whilst the local concentration of salbutamol used in the study was 
clearly enough to overcome airway beta-2-blockade conferred by propranolol, it was not 
enough to overcome antagonism of systemic skeletal muscle beta-2-adrenoceptors.  
Although this study did not have a control arm where placebo propranolol was given, it 
is already known that 5mg nebulised salbutamol on its own would be sufficient to 
induce significant hypokalaemia.133 
 
Heart rate showed a significant fall at 2 hours post-propranolol but this fall was not 
sustained at 4 hours post-propranolol, whilst markers of beta-2-blockade persisted. 
Whilst peak blood levels following dosing with propranolol occur at approximately 2 
hours, with an elimination half life of 4-6 hours this finding is unsurprising due to the 
relatively low dose of propranolol used and although non-selective, propranolol has a 
greater binding affinity to beta-2 than beta-1 adrenoceptors.59 Indeed a similar finding 
has been reported with low dose nadolol in terms of preferential beta-2/beta-1 
antagonism in man.142 The beta-2-adrenoceptor binding affinity of propranolol is 
actually higher than that of nadolol, while its beta-1 binding affinity is lower, 59 thus 
making propranolol well suited for use in trials in asthma where a high degree of beta-2-
adrenoceptor antagonism is required during the initial dose ramp. In this regard it has 
been shown that significant and near maximal up regulation of peripheral blood 
lymphocyte beta-2-adrenoceptors occurs after 2 days of oral propranolol at 160mg/day  
in healthy volunteers.144 
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Due to the known variability between subjects in the oral bioavailability of propranolol 
due to saturable first -pass kinetics, the study employed a stepwise dose regime. Whilst 
the starting dose of 10 or 20mg of propranolol is relatively low in comparison to the 
usual maintenance dose used in clinical practice for treatment of hypertension, angina 
and anxiety(usually 80-160mg/day), the study findings are clinically relevant since there 
was a clear demonstration of significantly sustained beta-2-blockade.  As this study was 
the designed primarily as a safety study using a contraindicated medication in asthma it 
was unethical to use a higher dose for initial exposure.   
 
This study has however shown through the measurements of IOS and serum potassium 
evidence of sustained beta-2-blockade at 4 hours following 10 or 20mg of propranolol. 
The limitations of this study are that it was pilot in design and thus a small sample size 
was used, however importantly there were no observed clinically relevant adverse 
effects with beta-blocker use in the study group.  Within the study design well 
controlled asthmatics taking inhaled corticosteroids were deliberately chosen, as such 
the first dose effects of propranolol were minimised. Thus the degree of 
bronchoconstriction seen in this study was less than seen by McNeill prior to the 
introduction of inhaled corticosteroids.61  
 
In conclusion, this study has demonstrated that a single low dose of oral propranolol 
caused a small but significant deterioration in airway calibre, which was more evident 
with impulse oscillometry rather than spirometry. Importantly nebulised salbutamol and 
ipratropium produced a full recovery of FEV1 and airway resistance after acute 
histamine induced bronchoconstriction in the presence of acute beta-blockade. This was 
achievable due to the relatively low dose of propranolol used in comparison with 
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salbutamol. Furthermore the use of muscarinic antagonist, ipratropium provided a non 
beta-adrenergic mediated method of bronchodilatation. Intravenous hydrocortisone did 
not potentiate salbutamol recovery post-histamine challenge. However in a real-life 
scenario of an individual suffering an asthma exacerbation whilst receiving beta-
blockers, intravenous corticosteroids remain vital due to their anti-inflammatory 
benefits. Since the greatest risk of beta-blockade is after first dose exposure, this study 
offers reassurance for proceeding to the evaluation of chronic dosing with propranolol 
as a potential treatment option for asthma. 
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5. CRITIQUE 
 
This study was designed primarily due to safety concerns regarding acute beta-blocker 
dosing in asthma. Whilst it is already known that the greatest risk of bronchospasm with 
beta-blockers is after administration of the first dose, the study attempted to address 
what   would   happen   in   the   “worst   case   scenario”   where   the   patient   suffered   from   a  
concurrent asthma attack.   In order to simulate this scenario, the study visits were 
designed as a 6 hour study visit where the patient underwent concurrent beta-blockade 
and histamine challenge testing.  
 
This study was incredibly challenging to perform and as with any clinical trial involving 
human subjects, ethical approval had to be approved prior to the study being 
commenced. There were major concerns as to whether this study could be justified due 
to the potential adverse effects of beta-blocker use in asthma.  In view of the clear risk 
associated with this study, and as a pre-requisite for study approval, the potential risk of 
death was included in the participant information sheet.  
 
In order to mitigate this risk, a relatively low dose of propranolol was used in a mild-to-
moderate group of asthmatics.  Whilst undoubtedly improving the safety of the study, it 
could be argued that the clinical implications of this study were biased as a result.  
Whilst I believe it is safe to conclude that this study showed no significant adverse 
effects of acute beta-blocker use in asthma, these findings are restricted to this study 
cohort and no conclusions can be drawn as to what would happen in a more severe 
group of asthmatics. Furthermore the dose of propranolol used in this study at 10 or 
20mg was lower than any dose routinely used in clinical practice and therefore the 
results cannot be extrapolated to higher doses of propranolol or other beta-blocker 
  
87 
formulations. This relatively low dose of propranolol was used due to ethical issues 
with regards to the greater risk of bronchospasm with higher dosing. Importantly the 
clinical findings of salbutamol reversibility being preserved in the presence of oral beta-
blockade could be simply due to the relatively low dose of propranolol being used.  
 
Finally the primary outcome of this study was to assess the impact of intravenous 
hydrocortisone on salbutamol reversibility post histamine challenge in the presence of 
concurrent beta-blockade.  The underlying hypothesis that hydrocortisone would 
improve salbutamol reversibility in comparison with placebo. This was based upon 
previous data from our department showing the potential for high dose systemic 
corticosteroids (200mg intravenous hydrocortisone with 50mg oral prednisolone) to re-
establish beta-2-adrenoceptor function.47  In the previous study by Tan, beta-2-
adrenceptor down-regulation was achieved by 4 weeks of sustained long-acting beta-
agonist use with formoterol.  On reflection the same degree of beta-2-adrenoceptor 
down-regulation would not be achieved with a single oral dose of propranolol, and 
therefore this may account for why no beneficial effects on salbutamol reversibility 
were seen with hydrocortisone.  
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CHAPTER 4: 
 
SENSITIVITY OF SPIROMETRY 
AND IMPULSE 
OSCILLOMETRY IN ACUTE 
BETA-BLOCKER INDUCED 
BRONCHOCONSTRICTION 
AND ACUTE BETA-AGONIST 
INDUCED 
BRONCHODILATATION IN 
ASTHMA 
 
 
 
Study Aims 
1. To compare the various indices of impulse oscillometry with standardised 
spirometry in the assessment of bronchoconstriction and bronchodilatation. 
2. To  determine  the  “signal  to  noise”  ratio  of  each  test,  allowing  an  analysis  of  
both effect size and responsiveness of each test. 
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1. INTRODUCTION 
Spirometry and Impulse oscillometry (IOS) are two distinct methods of assessing lung 
function and provide means of measuring change to airway tone following either a 
bronchoconstricting or bronchodilating stimulus. Unlike conventional spirometry, 
which is an effort dependent test, IOS is performed at tidal volume during normal 
breathing that assesses several components of respiratory physiology, namely airway 
resistance and pulmonary reactance.123 
 
Whilst the effects on spirometry and predominantly FEV1 have been extensively studied 
following beta-blocker use,61 the effects of beta-blocker induced bronchoconstriction on 
IOS are less well known. 
 
IOS is known to be a sensitive marker of airway dysfunction, but is commonly 
associated with a wider variation than spirometry.141 In the previous chapter IOS was 
shown to be more sensitive than spirometry at demonstrating beta-blocker induced 
bronchoconstriction, however the variability associated with IOS was not accounted for.  
When considering the relative sensitivities of spirometry and IOS it is important to 
determine   the  “signal   to  noise”  ratio  of each test thereby allowing an analysis of both 
the effect size and responsiveness of each test. 
 
Accounting for the variability of each test, by calculating standardised response means, 
in this chapter, the relative sensitivities of IOS and spirometry in the assessment of 
bronchoconstriction to propranolol and bronchodilatation to salbutamol were compared. 
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2. METHODS 
 
A post-hoc analysis of lung function data from the placebo limb of the randomised 
placebo-controlled double-blind crossover trial described within chapter 3 was 
performed. The methods within the reference study have been described previously 
however the key details and measurements specific to this study are reiterated here. 
Mild-to-moderate   persistent   stable   asthmatics   taking   ≤1000µg   day   beclomethasone 
dipropionate equivalent (BDP) of inhaled corticosteroids (ICS), FEV1 >80% predicted, 
aged 18-65yr who had AHR to histamine challenge were recruited.  All participants 
were non-smokers. 
 
On the study visit, each participant received a single dose of 10mg or 20mg of oral 
propranolol followed by histamine bronchial challenge testing (PC10) 4 hours later, with 
recovery to nebulised salbutamol 5mg.  Spirometry and IOS were measured pre and 2-
hour post beta-blocker, post histamine and 20 min post salbutamol. 
 
Spirometry and impulse oscillometry were performed in accordance with published 
guidelines.122,123  IOS is an effort independent method of assessing lung function by the 
use of sound waves being superimposed on normal breathing cycles.  A super Spiro 
spirometer (Micro Medical, UK) and IOS Jaeger Masterscreen (Germany) were used. 
Histamine Bronchial challenge testing was performed with the provocative dose of 
histamine required to cause a 10% fall in FEV1 being calculated.  A Mefar dosimeter 
was used with histamine concentrations of 0.3125 to 40mg/ml. 
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Data were analysed for normality with Shapiro-Wilk tests and Boxplots. Pre vs post 
percentage change (95%CI) values were calculated and compared with paired student t-
tests for spirometry and IOS indices following bronchoconstriction to propranolol and 
bronchodilatation to salbutamol. Standardised response means (SRM) were also 
calculated.  SRM is a relative measure of effect size and responsiveness. It allows the 
expression of the signal of change in an outcome relative to its variability.145 SRMs 
therefore express the signal (ie mean) to noise (ie standard deviation) ratio and is 
calculated as mean change in an outcome divided by the standard deviation of the 
difference.  Ideally a SRM would be greater than unity, however an SRM of 
approximately 0.20 is considered small, one of 0.50 indicates moderate responsiveness, 
and  those  of  ≥  0.80  are  considered  highly  sensitive.  As  SRMs  are  standardised  scores,  
the SRM for spirometry can be compared directly with the SRMs for impulse 
oscillometry. 145All statistical analyses were performed using SPSS version 17. 
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3. RESULTS 
A total of 13 participants (mean age, 34 years) completed the study (see table 5). Two 
participants withdrew as they could not complete the study visits for personal reasons. 
11 participants received 20mg of oral propranolol, 2 received 10mg as this dose was 
sufficient to cause >10% fall in FEV1 on the test-dose algorithm.  There were no 
adverse events following beta-blocker ingestion. 
 
All IOS indices showed a greater magnitude of response to propranolol (i.e. as 
%change) compared to spirometry. The greatest magnitudes of change were observed in 
R5-20 and AX, measurements of small airway resistance and pulmonary reactance.  
With regards to bronchodilator response, FEF25-75 demonstrated a greater magnitude of 
change to salbutamol compared to R5 and fres, however the greatest magnitude of 
change was again seen in R5-20 and AX (see figure 9). 
 
Figure 9. Percentage change for spirometry (FEV1, FEF25-75) and impulse oscillometry (AX, R5-
20, R5, fres) for the bronchoconstrictor response to propranolol and the bronchodilator response to 
salbutamol. 
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All IOS indices (R5, R5-R20, AX, fres) showed significant worsening of airways 
resistance or reactance to propranolol. FEV1 and not FEF25-75 showed significant 
deterioration post beta-blocker. Individual participant response post propranolol and 
salbutamol and their effects on FEV1  and R5% predicted are shown in figure 10. 
 
 
Figure 10. Individual participant percentage change for FEV1% and R5% bronchoconstrictor 
response to propranolol and the bronchodilator response to salbutamol. Data displayed with 
respective means and 95%CI. 
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After adjustment for test variability, by calculation of SRMs, IOS outcomes were better 
than spirometry post-bronchoconstriction with the highest SRM seen with R5.  All 
measures of IOS and spirometry showed a significant bronchodilator response post 
salbutamol with the greatest SRMs seen in fres and R5 (see table 9).
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4. DISCUSSION 
This is the first study, accounting for test variability to directly compare the sensitivities 
of impulse oscillometry and conventional spirometry when using beta-blockers as the 
bronchoconstricting stimulus.  Beta-blockers are avoided in asthma due to the concerns 
regarding potential bronchospasm.68  Subsequently trials involving beta-blocker use in 
asthmatics need to be performed with safety as the primary focus.   Participants enrolled 
into studies using contraindicated medications in asthma subsequently have mild-to-
moderate disease and thereby relatively preserved spirometry.102  As a result of this 
spirometry may be regarded as an insensitive measurement to assess 
bronchoconstriction and conversely bronchodilatation in these patients. 
 
In the previous chapter it was demonstrated that IOS is a more sensitive measurement 
for assessing beta-blocker induced bronchoconstriction, however the previous analysis 
did not account for the variability associated with IOS.  Standardised response means 
are highly informative measures calculated by dividing the mean change in an outcome 
by the standard deviation of the difference (ie, it is a measure of effect size or 
responsiveness). As the denominator examines response variance, it provides a sensitive 
indication of signal-to-noise ratio. As SRMs are standardised scores, they are routinely 
used to compare differing health related outcomes, which in the case of this study, 
allows the comparison of spirometry and IOS.145-148 Reflecting the greater magnitude of 
change seen with IOS outcomes, the highest standardised response means were also 
seen with IOS measurements. 
 
Impulse oscillometry is an alternative technique to assess changes in airway tone, which 
has been shown to be sensitive to measuring bronchodilatation to salbutamol and 
96 
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ipratropium within both asthma and COPD populations.141,149,150 IOS is an effort 
independent test, using oscillation of differing sound waves to derive a variety of output 
measurements thus determining both the degree of total  (R5) and peripheral airway 
resistance (R5-R20) and pulmonary reactance (AX, fres).   IOS does not include the 
forced expiratory manoeuvres required when performing spirometry, as a result, IOS is 
routinely used to good effect in paediatric populations as an alternative or adjunct to 
spirometry.151 Within this analysis the greatest magnitude of change to beta-blocker and 
beta-agonist use were seen within IOS measurements that are reflective of small airway 
dysfunction, namely R5-R20 and AX.  IOS is routinely used when determining small 
airway dysfunction has also been used to good effect in assessing asthma control in 
children.152 These findings reaffirm the importance of evaluating small airway disease 
in the asthmatic individual and demonstrating the ability of IOS to examine both small 
and large airway dysfunction independently in those with relatively preserved 
spirometry. 
 
In conclusion, IOS has been shown to be a more sensitive marker of 
bronchoconstriction to oral propranolol than spirometry, even when adjusted for greater 
test variation. This is true for both small changes (propranolol induced 
bronchoconstriction) and large changes (salbutamol induced reversal of histamine).  
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CHAPTER 5: 
 
 
RANDOMISED PLACEBO 
CONTROLLED TRIAL TO 
EVALUATE CHRONIC DOSING 
EFFECTS OF PROPRANOLOL 
IN ASTHMA 
 
 
Study Aims 
1. To evaluate whether chronic dosing with propranolol in asthma results 
in an improvement in airway hyper-responsiveness to methacholine and 
histamine challenge testing. 
2. To assess whether concurrent tiotropium prevents drug induced 
bronchoconstriction following chronic beta-blockade. 
3. To assess the tolerability of chronic dosing with propranolol in asthma 
by utilising a gradual dose-ramp regime. 
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1.  INTRODUCTION 
The evolution of the management of heart failure has shown the differing effects 
between acute and chronic beta-adrenoceptor antagonism. Despite the potentially acute 
deleterious effects on cardiac function in heart failure, chronic beta-blocker use results 
in beneficial effects on both ejection fraction and morbidity and mortality.91 The ability 
to tolerate beta-blockers in heart failure was achieved by gradually increasing the dose, 
and as a result beta-blockers are now considered part of standard therapy. The observed 
effects of beta-blockers in heart failure prompted an examination of the putative 
therapeutic role of beta-blockade in asthma, questioning despite the potential acute 
deleterious effects, whether there were any benefits of chronic beta-blockade.95 This 
hypothesis was also fuelled by emerging data suggesting chronic exposure to long 
acting beta-agonists may worsen asthma control due to beta-2-adrenoceptor down 
regulation and associated desensitisation of response, in turn pointing to the possibility 
that that antagonist of the agonist might be beneficial in causing the opposite 
effects.137,153 
 
The first evidence in support of this hypothesis was derived from studies using the 
ovalbumin-sensitised mouse model of asthma. Chronic exposure to nadolol produced 
bronchoprotection against methacholine challenge (a direct acting cholinergic 
spasmogen which induces airway hyper-responsiveness), in conjunction with reduced 
airway inflammation and mucous metaplasia, and simultaneous up-regulation of airway 
beta-2-adrenoreceptors.98-100 These initial studies led to two open label pilot studies in 
steroid naïve asthmatics, with chronic nadolol dosing achieving significant 
improvements in methacholine induced airway hyper-responsiveness compared to 
baseline. 102,104  These results might appear to be counterintuitive since anti-cholinergic 
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medication prevents beta-blocker induced bronchoconstriction.10 Hence one would 
predict that beta-blockers would increase rather than decrease cholinergic tone, 
therefore resulting in augmented methacholine responsiveness.  This in turn questions 
as to whether the previously observed reduction in methacholine response with beta-
blockers is specific to the cholinergic pathway per se, or whether attenuated airway 
hyper-responsiveness (AHR) to other spasmogens not acting through the muscarinic 
receptor such as histamine would also be demonstrated. 
 
In order to assess the putative effects of propranolol on AHR, within this study both 
methacholine and histamine challenge testing was used, in order to evaluate different 
signaling direct acting pathways on airway smooth muscle.  Due to ethical concerns 
regarding the safety of propranolol especially on initial exposure, this study enrolled 
stable asthmatics controlled on inhaled corticosteroid (ICS), to mitigate the risk of 
potentially inducing acute bronchoconstriction in the presence of untreated asthmatic 
inflammation. To further reduce this risk of propranolol induced bronchoconstriction a 
mirror the dosing regime of beta-blockers in heart failure, a gradual dose titration 
regime was used. Furthermore based upon previous work by Ind et al, demonstrating the 
ability for the inhaled anti-cholinergic oxytropium in preventing propranolol induced 
bronchoconstriction,10 study participants were administered with concomitant 
tiotropium in the dose up-titration phase.  
 
The method by which anti-cholinergic medication prevents beta-blocker induced 
bronchoconstriction is poorly understood however is thought to involve crosstalk 
between muscarinic M2 autoreceptors and beta-2-adrenoceptors, which are both 
inhibitory to the release of acetylcholine, thereby preventing bronchoconstriction.11  In 
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the presence of acute beta-blockade, the inhibition of acetylcholine is removed and 
subsequent bronchoconstriction by increases in airway hyper-responsiveness and airway 
tone occurs.  
 
Within this study hypothesis, whilst is it postulated that chronic beta-blockade pre-
synaptically may reduce airway hyper-responsiveness, post-synaptically muscarinic M3 
autoreceptor induced bronchoconstriction would still occur with subsequent increases in 
airway tone. Thus the addition of tiotropium to chronic beta-blockade may result in a 
reduction of M3 induced bronchoconstriction in addition to the potential reduction in 
pre-synaptic AHR observed with chronic beta-blockade (see figure 11). 
 
With these reassurances, this chapter examines the safety and effects of chronic 
propranolol use versus placebo, in the presence of concurrent inhaled tiotropium, in 
mild-to-moderate asthmatics taking inhaled corticosteroids. 
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2. METHODS 
Study Design 
A double-blind randomised placebo controlled crossover trial was performed (see fig 
12).   The Tayside Medical Research Ethics Committee gave approval before 
commencement of the trial. The study was registered with http://www.clinicaltrials.gov 
(NCT01074853). 
 
Study Design 
Persistent mild-to-moderate asthmatics, aged between 18 to 65 years, with FEV1 >80% 
predicted and diurnal FEV1 variation <30% who were taking  ICS  ≤1000μg  BDP  per  day  
or equivalent were recruited. Participants were required to demonstrate airway hyper-
responsiveness to methacholine bronchial challenge with a PC20 <8mg/ml. Participants 
were all non-smokers.  Exclusion criteria included: an asthma exacerbation within the 
last six months, resting systolic blood pressure <110mmHg, heart rate <60 bpm, history 
of arrhythmias, concurrent negative chronotropic medications. 
 
Following a screening visit to assess eligibility, a one to two week run-in period to 
assess asthma disease stability was performed using electronic domiciliary FEV1 
measurements, prior to randomisation. Participants continued their normal dose of ICS 
throughout the study. Participants who usually took a combination inhaler of ICS and 
LABA were switched to the equivalent dose of ICS only for the duration of the study. 
For reliever use, participants were issued with both ipratropium bromide and salbutamol 
to be used in a staged fashion as required i.e. ipratropium as first line reliever, followed  
if necessary by salbutamol as second line.
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Participants underwent initial dose titration with either propranolol or matched placebo 
at weekly intervals (10mg twice daily, 20mg twice daily, 80mg LA once daily) as 
tolerated over a two to four week period, based upon the dose titration algorithm (figure 
13). Blinding   and   randomisation   was   performed   by   St   May’s   Pharmaceutical Unit, 
Cardiff and Vale University LHB, Wales. 
 
Following the first dose of propranolol or placebo, and at every subsequent up-titration 
visit participants were observed within the department for three hours with serial 
pulmonary function recorded. Once the maximal dose of propranolol or placebo was 
established the treatment was then continued for a further four weeks (plateau phase). 
Tiotropium was given concurrently throughout the dose titration period and for the first 
two weeks of the plateau phase. In total each treatment limb (including dose titration 
and plateau phase) continued for a minimum of six weeks and maximum of eight weeks 
of randomised treatments. 
 
Participants were seen at weekly intervals, for assessment of FEV1 domiciliary 
measurements, spirometry, impulse oscillometry (IOS), blood pressure (lying and 
standing)  and  heart  rate.  Participant’s  symptoms  and  physiological  measurements  were  
considered and randomised treatment was titrated up or down accordingly. 
 
Methacholine challenge PC20 followed by sequential salbutamol and ipratropium 
bromide reversibility was performed at the end of each treatment period.  Histamine 
challenge PC20 with reversibility was performed after two weeks of plateau phase with 
concurrent tiotropium and four weeks of plateau phase (i.e. with no concurrent 
tiotropium).  Following completion of the first treatment limb participants received their 
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usual ICS alone, for a two week period prior to crossover.  Participants were continued 
any anti-histamines and leukotriene receptor antagonists (LTRA) throughout the study 
with the exception of stopping for 5 days prior to any bronchial challenge test visit. 
 
Measurements 
Spirometry and IOS were performed in accordance with published guidelines.122,123 A 
SuperSpiro spirometer (Micro Medical, UK) and IOS Jaeger Masterscreen (Germany) 
were used.  A Mefar dosimeter was used for Methacholine and Histamine Bronchial 
Challenges. The provocative concentration required to cause a 20% fall in FEV1 was 
calculated (PC20). 
 
Statistical Analysis 
Data were assessed for normality with the Shapiro-Wilk test and Box-plots. The 
primary outcome was methacholine  PC20. The null hypothesis was that there was no 
significant difference in methacholine PC20 following propranolol compared to placebo.  
An a priori calculation predicted 16 patients would ensure 80% power, with an D-error 
of 0.05 (two tailed), in order to detect a minimal important difference of one doubling 
dilution shift in methacholine PC20. For methacholine and histamine challenge, data 
were logarithmically transformed prior to analysis and then calculated as doubling 
dose/dilution change from placebo. For all outcomes, comparisons were made by a 
multi-factorial analysis of variance model, including sequence, visit, treatment and 
patient effects, with Bonferroni corrections for pairwise comparisons.  For salbutamol 
and ipratropium bromide recovery post bronchial challenge testing, areas under the time 
response curve for percentage change from baseline were calculated. All analysis was 
performed using SPSS version 18. 
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Figure 13. Dose Titration Algorithm 
No# Yes#
No#
No#
No#
Yes#
Yes#
Yes#
Asymptomatic+Symptomatic+
Spirometry,#Blood#
Pressure#(BP),#Heart#
Rate#(HR)#and#
domiciliary#FEV1#
measurements#
Systolic#BP#>95#
mmHg#
HR#>55bpm#
FEV1#>65%#
Domiciliary#
FEV1#variation#
<30%#
Potential#
Cardiac#or#
Respiratory#
side#effects##!
Systolic#BP#>95#
mmHg#
HR#>55bpm#
FEV1#>65%#
Domiciliary#
FEV1#variation#
<30%#
Are#symptoms#
‘Severe’#
(distressing,#
unpleasant#or#
dangerous)?#
Reassessment#
#at#1#week#
intervals#
Continue(
current(
dose(
Reduce(dose(
or(withdraw(
if(on(
minimum(
dose(
Up5titrate(
therapy(to(
next(dose(or(
continue(
maximum(
dose(
Systolic#BP#<90#
mmHg#
HR#<50#bpm#
FEV1<60%#
Domiciliary#
FEV1#variation#
>30%#
Reduce(dose(or(
withdraw(if(on(
minimum(dose(
  
109 
3. RESULTS 
21 participants were randomised of which, 18 participants (10 female, 8 male) 
completed per protocol. Mean age (SEM) was 36 (4). 17 participants achieved dose 
titration to the maximal propranolol dose. Baseline characteristics are shown in table 10. 
Three participants withdrew during the study due to: practical difficulties in completing 
study visits; hypotension; lower respiratory tract infection (figure 14). 
 
 
Figure 14. Study Consort diagram 
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 Airway Hyper-responsiveness 
No significant difference was observed in methacholine challenge PC20 following 
chronic propranolol exposure compared to placebo, geometric mean mg/ml: 2·57 
(95%CI 1·13 to 5·85) versus 2·50 (95%CI 1·14 to 5·50), -i.e. a mean doubling dilution 
difference (DDD) of  0·04 (95%CI -0·56 to 0·63), p=0·89 (figure 15).  
 
 
Figure 15. The effect of chronic treatment with propranolol on methacholine provocation 
concentration causing a 20% fall in FEV (PC20). Data for each participant are displayed as the 
doubling dose in methacholine PC20 values between propranolol versus placebo. 
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After two weeks chronic dosing with propranolol, whilst receiving concurrent 
tiotropium, no significant difference was seen with histamine challenge PC20 for 
propranolol versus placebo as geometric mean mg/ml: 2·11 (95%CI 1·33 to 3·33) 
versus 2·52 (95%CI 1·64 t0 3·85) ,i.e. a DDD of  0·26 (95%CI -0·36 to 0·87), p=0·39 
(figure 16). 
 
Following the cessation of tiotropium for 14 days, after a further two weeks of chronic 
dosing with propranolol, no significant difference was seen with histamine challenge 
PC20 for propranolol versus placebo as geometric mean mg/ml: 1·73 (95%CI 1·10 to 
2·73) versus 2·32 (95%CI 1·65 to 3·27), i.e. a DDD of  0·42 (95%CI -0·09 to 0·93), 
p=0·10 (figure 16). 
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Systemic beta-blockade 
Salbutamol induced chronotropic response, measured at the end of each study period, 
(i.e recovery post histamine challenge, study visit four or eight) was significantly 
blunted following propranolol in comparison with placebo: mean difference 25 bpm 
(95%CI 14 to 37), p<0·001. Resting heart rate was also significantly lower following 
chronic propranolol dosing: mean difference 5 bpm (95%CI 1 to 9), p<0·001 (figure 
17). No differences were seen for supine systolic or diastolic blood pressure at the end 
of each study period (visit four or eight), for placebo versus propranolol: mean 
difference 3 mmHg (95%CI -1 to 7), p=0·11, and 2 mmHg (95%CI -2 to 5), p=0·26. 
 
 
 
 
Figure 17. Salbutamol Response following Chronic Beta Blockade or Matched Placebo.  
Data displayed as mean (95%CI). 
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Recovery to Salbutamol and Ipratropium post challenge 
Following methacholine challenge, staged recovery to nebulised salbutamol and 
ipratropium  showed a significant overall difference between propranolol and placebo as  
AUC %.min (SEM) : 4077·4 (102)  versus 4362·5 (102), mean difference: 285·1 
(95%CI 34·6 to 535·7), p=0·028.  No significant difference was seen at 20 mins post 
salbutamol for propranolol versus placebo as FEV1% predicted mean difference: 5·05 
(95%CI -0·13 to 10·24), p= 0·055 (figure 18). Figure 5.
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Figure 18. Salbutamol and ipratropium recovery after methacholine challenge.  
Data are displayed as mean (95%CI).  SAL: salbutamol, IB; ipratropium bromide. 
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Comparisons of recovery post histamine challenges whilst receiving concurrent 
tiotropium showed a significant difference in staged salbutamol and ipratropium 
recovery for propranolol versus placebo, as AUC %.min (SEM) : 4082·9 (94) versus  
4413·6 (97), mean difference 330·8 (95%CI 208·8 to 452·8), p=0·01. Furthermore, at 
20 minutes post salbutamol the response was significantly different for propranolol 
versus placebo as FEV1% predicted mean difference 4·94 (95%CI 1·10 to 8·79), 
p=0·015. Following the cessation of tiotropium, after a further two weeks of chronic 
dosing with propranolol, there remained a significant difference versus placebo in 
staged salbutamol and ipratropium recovery, as AUC %.min (SEM) 4061·8 (94) versus 
4363·7 (99), mean difference 301·8 (95%CI 190·5 to 413·1), p=0·016. A significant 
difference was present at 20 minutes post salbutamol for propranolol versus placebo as, 
FEV1% predicted mean difference 5·28 (95%CI 2·54 to 8·01), p=0·001 (figure 19). 
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Effects on Pulmonary Function and Airway Inflammation 
FEV1 % predicted prior to methacholine challenge, without concurrent tiotropium, 
(study visit three or seven) showed a fall with propranolol versus placebo amounting 
to a 4·3% (95%CI -0·6 to 9·2) p=0·08. Measured at the end of each study period, (i.e 
study visit four or eight) prior to histamine challenge, there was a difference in FEV1 
% predicted  2·4% (95%CI -0·1 to 4·8), p=0·055 without tiotropium, and a difference 
of  3·2% (95%CI 0·05 to 6·3), p=0.046 with concomitant tiotropium  (at study visit 
two or six). 
 
No significant difference was seen in R5% predicted measured prior to histamine 
challenge at the end of each study period, (study visit four or eight) following 
propranolol versus placebo: mean  difference 3·65% (95%CI -14·7 to 22·0), p=0·68. 
In terms of airway inflammation measured by FENO, there was no significant 
difference following propranolol versus placebo, as geometric mean (SEM) 28·0 ppb 
(10·1) versus 25·3 ppb (7·6), amounting to a geometric mean fold difference of 1·11 
(95%CI 0·70 to 1·16), p=0·41. 
 
Asthma Control and Quality of Life 
At the end of the study period, no significant difference was found between 
propranolol versus placebo for ACQ, mean difference: 0·18 (95%CI -0.23 to 0·58), 
p=0·79.  Furthermore no significant difference was seen in the mini-AQLQ, mean 
difference: 0·14 (95%CI -0·19 to 0·46), p=0·84. 
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4. DISCUSSION  
The purpose of this study was to assess the effects of chronic propranolol in patients 
with stable persistent asthma as add on therapy to inhaled corticosteroids. Previous 
open-labeled studies have shown attenuation of methacholine AHR with nadolol 
compared to baseline in steroid–naïve asthamatics.102 The results of this study showed 
no significant effect of propranolol compared to placebo on either methacholine or 
histamine AHR. 
 
Airway remodelling describes structural changes in the human airway associated with 
asthmatic inflammation and is a complex process that involves all component tissues 
of the airway from the epithelium to the adventitia.  Deemed irreversible, remodelling 
changes contribute to thickening of airway walls with subsequent airway narrowing, 
bronchial hyper-responsiveness, airway oedema and mucous hypersecretion. Airway 
remodelling is associated with poor clinical outcomes among asthmatic patients.154  
Although no effects were demonstrated on airway smooth muscle, the proposed 
benefits seen in murine models of asthma with chronic nadolol being able to reduce 
mucous metaplasia and mucin production was intriguing.100 
 
Although using beta-blockers in asthma may at first sight seem counterintuitive, there 
is evidence to suggest that chronic long-acting beta-2-agonist therapy with inhaled 
corticosteroid use results in down-regulation and sub-sensitivity of the beta-2-
adrenoceptor,155,156 sometimes with worsening asthma control.157,158 Therefore the 
paradox for beta-2-adrenoceptor up-regulation and increased sensitivity following 
chronic beta-blocker use in asthma is intriguing.137 In the same way that LABAs are 
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only routinely given in conjunction with ICS, it could be argued that when examining 
the effects of chronic beta-blocker use in asthma, this should also be performed as add 
on therapy to pre-existing ICS, as was the case in the present study. Unlike previous 
open label chronic dosing studies with nadolol in steroid naïve patients, no attenuation 
of airway hyper-responsiveness to methacholine following chronic propranolol 
compared to placebo was seen when added to ICS. Pointedly even when using a 
spasmogen acting via a different pathway, namely histamine, there was still no 
difference in comparison to placebo, regardless of presence or absence of concurrent 
tiotropium use. 
 
In the absence of any worsening of airway hyper-responsiveness it could be assumed 
that the presumed deleterious chronic effects of beta-2-blockade in asthma might 
conceivably result in increased airway tone. At the final visit prior to histamine 
challenge there was a small worsening in FEV1% predicted following propranolol 
compared to placebo amounting to a 2.4% difference, this was despite systemic beta-
2-blockade being evident as attenuation of salbutamol induced tachycardia. For post 
challenge recovery to salbutamol, the degree of reversibility remained mostly 
preserved following chronic propranolol, with or without the presence of concomitant 
tiotropium.  
 
The rationale for long acting anticholinergic therapy was to obviate any initial 
worsening of airway calibre during the initial up titration with propranoloI,10 when 
patients would be most vulnerable before beta-2-adrenoceptor adaptation had 
occurred, which is thought to take at least two weeks with propranolol on peripheral 
blood mononuclear cell cAMP response to isoprenaline. 138,139 However data on beta-
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2-adrenoceptor binding density on peripheral blood mononuclear cells with 
propranolol has shown near maximal up regulation after only two days reaching a 
peak after ten days.144  
 
When reviewing historic case reports of beta-blocker use in asthmatics, the greatest 
concerns of bronchoconstriction have been with acute dosing. In chapter 3 it was 
demonstrated that nebulised salbutamol and ipratropium can achieve a full recovery 
of pulmonary function post histamine challenge testing despite the presence of 10 or 
20mg of propranolol given as single acute dose, in steroid treated asthmatics. In the 
present study it has been shown that by means of slow dose titration, doses of 
propranolol up to 80mg can be well tolerated in patients with stable steroid treated 
persistent asthma, without any associated deleterious effects on ACQ or AQLQ. 
Indeed the mean differences in either ACQ or AQLQ were well within the accepted 
minimal important difference of 0.5 units for both outcomes. This finding alone 
would challenge current clinical equipoise that asthmatics should never be given a 
beta-blocker let alone a non-selective agent like propranolol.95 This in turn may 
suggest that as in heart failure, chronic beta-blockade can be given relatively safely 
without deleterious effects when given by a gradual dose escalation regime, whilst 
allowing the beta-2-adrenoceptors to adapt. 
 
Although this study did not demonstrate any significant deleterious effects of chronic 
propranolol dosing within carefully chosen asthmatic patients, the study also failed to 
show any beneficial effects in comparison to placebo control. Despite being non-
selective beta-blockers, whether the use of propranolol in this study rather than 
nadolol has affected findings is unclear. In this regard both drugs exhibit inverse 
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agonist activity (i.e. an ability to effectively switch off the receptor), as well acting as 
conventional competitive receptor antagonists.159 
 
In conclusion, this study has shown that by means of a placebo controlled design, that 
the non-selective beta-blocker propranolol may be safe to use without any worsening 
of AHR and only a small effect on pre-challenge pulmonary function, in carefully 
selected stable steroid treated asthmatics. These results cannot be extrapolated to more 
severe asthmatics or when propranolol is given for greater than 6-8 weeks duration. 
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5. CRITIQUE 
 
This study was designed to assess the effects of chronic propranolol dosing on airway 
hyper-responsiveness. As previously discussed murine models and open label studies 
in humans have suggested putative benefits with chronic beta-blockade in asthma.   
 
As with the acute dosing study, this study was restricted by ethical concerns. These 
concerns resulted in a maximum dose of 80mg being used and also relatively short 
study duration of 6-8 weeks.  It therefore remains unknown as to whether an increase 
in maximum dose or study duration would have resulted in any therapeutic benefit 
being seen.   
 
With regards to the primary outcome, methacholine challenge PC20 was chosen 
primarily because it was the study outcome used in the previous open label studies 
which suggested therapeutic benefits.  Whilst the use of a PC20 is an accepted 
measurement of airway hyper-responsiveness, with hindsight the slope of the dose 
response curve could have been utilised to assess for subtle changes in airway hyper-
responsiveness. In order to ensure that any potential benefit seen was not unique to 
methacholine challenge, histmaine challenge testing was used, both challenges are 
however direct bronchial challenges.  Mannitol, as an example of an indirect 
challenge test that may have been better suited as an alternative challenge test.  The 
basis for this is that indirect challenge tests stimulate inflammatory cells, epithelial 
cells and nerves to release mediators that act on specific receptors of the smooth 
muscle and induce its contraction with resultant airway narrowing, thus better 
mimicking the inflammatory cascade seen in asthma rather than a pure 
pharmacological challenge test such as methacholine.   
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CHAPTER 6: 
 
EFFECTS OF INTRAVENOUS 
CARDIO-SELECTIVE BETA-
BLOCKADE AND CHRONIC 
ORAL NON-SELECTIVE BETA-
BLOCKADE IN ASTHMA 
 
 
 
 
Study Aims 
1. To assess the pulmonary effects of acute intravenous esmolol dosing in 
mild-to-moderate asthmatics taking inhaled corticosteroids. 
2.  To assess the effects of first dose exposure to oral propranolol and the 
subsequent effects at dose up-titration.  
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1. INTRODUCTION 
 
Within the previous chapter, although a lack of therapeutic benefit was seen with 
chronic propranolol dosing, within the study participants it was demonstrated that 
non-selective beta blockade can be administered relatively safely in selected mild-to-
moderate asthmatics. 
 
Beta-blockers are integral in the treatment of cardiovascular disease. Despite their 
proven benefits, beta-blockers are avoided in asthmatics due to concerns of 
bronchoconstriction.68 These concerns led to a consensus statement from the 
European Society of Cardiology stating that, a history of asthma should be considered 
a contra-indication to the use of any beta-blocker.71 
 
In addition to data within this thesis showing a lack of any significant deleterious 
effects with non-selective beta-blocker use in asthma, as previously discussed the 
meta-analysis by Salpeter suggests that cardio-selective beta-blockers can be given 
relatively safely within patients with a history of obstructive airway disease.77  
 
Several safety issues are likely to influence the prescription of beta-blockers in 
asthma. In addition to potential bronchoconstriction upon first exposure, subsequent 
up-titration of beta-blockers results in further exposure and potential risk. Up-titration 
is commonly performed in the community and without direct medical supervision. 
Moreover the presence of beta-2-adrenoceptor antagonism might conceivably 
attenuate the response to concomitant beta-agonist inhaled therapy. 
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The concern of beta-blocker use in asthma led partly to the development of ivabradine 
as an alternative negatively chronotropic medication, which does not results in any 
bronchoconstriction when used in asthma.160 
 
Although there were no demonstrable beneficial effects on AHR with propranolol, the 
data generated allows an evaluation of the safety and tolerability of propranolol in 
asthma. Within the study described in the previous chapter, prior to randomisation a 
subgroup of participants were given a single intravenous injection of the cardio-
selective beta-blocker esmolol with the effects on pulmonary function assessed. The 
results of this subgroup analysis are discussed in this chapter. In addition the observed 
pulmonary effects of first dose exposure to oral propranolol and the subsequent 
effects at dose up-titration, in the presence of concurrent tiotropium are discussed. 
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2. METHODS 
 
A post-hoc analysis of a double-blind randomised placebo controlled trial of 
propranolol in mild-to-moderate asthmatics was performed. The study was registered 
with http://www.clinicaltrials.gov (NCT01074853). 
 
Mild-to-moderate asthmatics, aged between 18-65 years, FEV1 >80% predicted and 
diurnal FEV1 variation <30%, taking inhaled corticosteroid ≤1000μg/day    
beclomethasone dipropionate  equivalent dose were recruited. Participants were 
required to demonstrate airway hyper-responsiveness (AHR) to methacholine 
bronchial challenge PC20 <8mg/ml. Participants were all non-smokers. Exclusion 
criteria included: asthma exacerbation within the last six months, systolic blood 
pressure <110mmHg, heart rate <60 bpm, history of arrhythmias, concurrent negative 
chronotropic medications. 
 
Prior to randomisation a subgroup of participants underwent a safety visit and 
received a single intravenous bolus dose of esmolol (0.5mg/kg).  Spirometry, impulse 
oscillometry and heart rate and blood pressure were recorded pre and post acute 
esmolol dosing at 2, 8, 16 and 32 minutes. 
 
As previously discussed, participants then underwent dose titration of propranolol or 
matched placebo at weekly intervals (10mg twice daily, 20mg twice daily, 80mg LA 
once daily) as tolerated over a two to four week period.  Following the first dose of 
propranolol (or matched placebo) at 10mg, and at every subsequent up-titration visit 
(ie the first dose exposure to 20mg and 80mg) participants were observed within the 
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department for three hours with serial pulmonary function, heart rate and blood 
pressure recorded. Tiotropium was given concurrently during the dose titration period 
with propranolol (or matched placebo). The full methods of the main protocol have 
been described in detail in chapter 5. In this chapter only report the subgroup of 
participants who received an initial intravenous esmolol in addition to their 
propranolol up-titration data is discussed. 
 
Outcome Measures 
The main outcome measures were the effects on pulmonary function following acute 
esmolol and propranolol use. Spirometry and impulse oscillometry were recorded. 
 
Measurements 
Spirometry was performed in accordance with published guidelines.122 Impulse 
oscillometry (IOS) was performed according to published guidelines.123  A 
SuperSpiro Spirometer (Micro Medical, UK) and IOS Jaeger Masterscreen 
(Germany) were used. Bronchoconstriction was reflected as either a fall in forced 
expiratory lung volume as FEV1 or an increase in airway resistance as R5. Asthma 
control questionnaires were performed.161 
 
Statistical Analysis 
Data were assessed for normality with the Shapiro-Wilk test and Box-plots. The 
primary outcome was change in FEV1 post esmolol administration. For all outcomes, 
comparisons were made by a multi-factorial analysis of variance model with 
Bonferroni corrections for pairwise comparisons.  All analysis were performed using 
SPSS version 21 (Chicago, IL). 
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3. RESULTS 
 
12 participants (7 female, 5 male) underwent both esmolol and propranolol dosing 
and were used for the present analysis. No participant that received esmolol failed to 
be randomised and subsequently each participant received propranolol. Mean age 
(SEM) was 37(5). Baseline characteristics are shown in table 11. 
Subject/Sex Age (years) FEV1% 
 
 
FEV1/FVC 
Ratio Methacholine PC20 (mg/ml) 
BDP 
equivalent 
daily 
dose(µg) 
1/F 21 92 0·78 0·92 400 
2/F 64 99 0·71 2·48 400 
3/F 31 85 0·75 0·99 500 
4/M 48 85 0·68 2·0 500 
5/F 65 103 0·69 0·71 200 
6/M 29 98 0·71 1·36 100 
7/M 57 106 0·81 3·45 1000 
8/M 20 91 0·76 3·71 400 
9/F 19 91 0·83 0·67 400 
10/M 19 90 0·85 1·73 200 
11/F 25 91 0·85 2·4 200 
12/F 50 88 0·67 1·13 400 
Mean (SEM) 37(3) 93(2) 
 
0.76(0.02) 1.54 (1.06- 2.23) 392 (67) 
 
Table 11. Participant Demographics 
Data displayed as geometric mean (95%CI). Data shown as % predicted for age, gender, race.  
FEV1: Forced Expiratory volume in 1 second; FVC: Forced Vital Capacity; BDP:beclomethasone 
dipropionate.
 130 
Acute cardio-selective beta-blockade – effects on pulmonary function 
Pulmonary function was assessed pre-esmolol dosing and post-esmolol dosing at (2 
mins, 8 mins, 16 mins and 32 mins). No significant differences were seen in FEV1% 
predicted following an intravenous esmolol bolus.  Mean change in FEV1% predicted 
(95% CI) were: 2 minutes post esmolol; -0.58%  (-2.96  to 1.79), p=0.99, 8 minutes; 
0.42%  (-3.17 to 4.00), p=0.99, 16 minutes; 0.75%  (-2.73 to 4.22 ), p=0.99, and 32 
minutes; 0.67%  (-3.51 to 4.85), p=0.99. (see figure 20). 
 
 
 
Figure 20. Effect of Esmolol on FEV1% predicted and Heart Rate. 
 Data displayed as Mean (SEM). *significant difference from baseline p<0.05 
 
No significant differences were seen in total airway resistance as R5% predicted post 
esmolol. Mean change in R5% predicted (95% CI) were: 2 minutes post esmolol; 1.6%  
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(-12.65 to 9.44), p=0.99, 8 minutes; 1.85%  (-12.49 to 8.78), p=0.99, 16 minutes; -
0.51%  (-13.43 to 12.40), p=0.99 and 32 minutes; -1.1%  (-11.64 to 9.44), p=0.99. 
 
Acute cardio-selective beta-blockade – effects on blood pressure and heart rate 
Significant reductions in heart rate were seen at 2 and 32 minutes post esmolol dosing. 
Mean fall (95%CI) in heart rate at 2 minutes post esmolol: -4.7  (-7.9 to -1.3), p=0.002 
and 32 minutes; -4.4 bpm (95%CI -7.8 to -1.1), p=0.003 (figure 19). A significant small 
reduction was also seen in systolic blood pressure at 2 and 32 minutes post esmolol 
dosing. Mean fall (95%CI) in systolic blood pressure at 2 minutes post esmolol: -
5.9mmHg (95%CI -11.4 to -0.41), p=0.03 and 32 minutes: -5.7mmHg (95%CI-11.2 to -
0.17), p=0.04. 
 
Acute non-selective beta-blockade with concurrent tiotropium. – effects on pulmonary 
function 
A non-significant increase in FEV1% predicted was seen 30minutes post 10mg 
propranolol (with tiotropium); mean difference 3.9% (95%CI -0.4 to 8.2), p=0.084, 1 
hour post dose; 3.8% (95%CI -1.3 to 8.8), p=0.26, 2 hours post dose; 3.3% (95%CI -2.6 
to 9.1), p =0.80, and 3 hours post dose; 3.3% (95%CI -3.6 to 10), p=1.0 (figure 21). 
Falls in R5% predicted were seen at 30minutes post 10mg propranolol (and tiotropium); 
mean difference -39.3% (95%CI -69.9 to -8.8), p=0.009, 1 hour post dose; -32.8% 
(95%CI -58.8 to -6.8), p=0.01, 2 hours post dose; -31.3% (95%CI -58.2 to -4.3), p=0.01, 
and 3 hours post dose; -35.8% (95%CI-72.5  to 0.95), p =0.06. 
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Figure 21. Protective Pulmonary Effects of Tiotropium post 10mg dose of propranolol.  
Data displayed as mean (SEM). 
 
Compared to matched placebo there were no significant differences observed in FEV1% 
and R5% predicted 3 hours post 10mg of propranolol in the presence of concurrent 
tiotropium (table 12). 
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Up-titration of non-selective beta-blockade with concurrent tiotropium 
 
No evidence of bronchoconstriction was demonstrated in either FEV1% or R5% 
predicted following 1st dose exposure to either the 20mg or 80mg dose of propranolol in 
the presence of concurrent tiotropium (figure 22). 
 
 
 
 
Figure 22. Protective Effects of Tiotropium on FEV1% predicted at propranolol up-titration. 
 
Mean increase in FEV1% predicted 30 minutes post 20mg of propranolol (with 
tiotropium); 0.33%  (95%CI -1.6 to 2.3), p=0.99, and 3 hours post dose; 1.3%  (95%CI -
1.6 to 4.1), p=0.99. Mean fall in R5% predicted 30 minutes post 20mg of propranolol 
(with tiotropium); -4.0% (95%CI -17.8 to 9.7), p=0.99, and 3 hours post dose, -
7.7%(95%CI -21.7 to 6.2), p=0.80. 
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Mean increase in FEV1% predicted 30 minutes post 80mg of propranolol (with 
tiotropium); 0.92%  (95%CI -1.26 to 3.09), p = 0.99 and 3 hours post dose; 1.25%  
(95%CI -3.56 to 6.06), p=0.99. Mean fall in R5% predicted 30 minutes post 80mg of 
propranolol (with tiotropium); -5.5%  (95%CI -20.3 to 9.2), p=0.99 and 3 hours post 
dose; -7.2%  (95%CI -28.9 to 14.5), p=0.99. 
 
Compared to matched placebo there were no significant differences observed in FEV1% 
and R5% predicted in the presence of tiotropium, except for after the 80mg dose of 
propranolol for R5% which amounted to a mean difference of 9.4%, p=0.03 (table 11). 
 
Non-selective beta-blockade – effects on heart rate and blood pressure 
Heart rate significantly fell 3 hours post 10mg of propranolol; -11bpm (95%CI -15 to -
7), p<0.001, post 20mg of propranolol; -6bpm (95%CI -10 to -1 ), p=0.013, and post 
80mg of propranolol; -7bpm (95%CI-15 to -1 ), p=0.049. 
 
No significant change was seen in supine systolic blood pressure post 10mg of 
propranolol; mean difference 2mmHg (95%CI -3 to 7), p=0.40, post 20mg of 
propranolol 2mmHg ( 95%CI -4 to 7), p=0.53, and post 80mg of propranolol; 4mmHg 
(95%CI -2 to 9), p=0.19. 
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4. DISCUSSION 
 
The aim of the present study was to assess the effects on pulmonary function of both 
cardio-selective and nonselective beta-blockade. Esmolol is highly cardio-selective in 
exhibiting a 34 fold higher affinity for beta-1 versus beta-2 adrenoceptors.162 This along 
with the short-duration of action of esmolol (half-life of 9 minutes), made it ideally 
suited for assessing safety in asthma. As part of the initial study protocol, it was decided 
that if an individual demonstrated significant adverse pulmonary effects with 
intravenous esmolol, they would not proceed to oral propranolol. 
 
This analysis has demonstrated that in a cohort of stable mild-to-moderate asthmatics, 
acute dosing with intravenous esmolol results in no significant adverse effects on 
pulmonary function, despite evidence of systemic beta-1-blockade with reduced heart 
rate and blood pressure. Given that intravenous esmolol avoids first pass inactivation, 
the lack of acute bronchoconstriction is reassuring.  
 
Whilst the use of a forced expiratory manouevre with spirometry (as FEV1) is 
considered the gold standard method for assessing airway calibre, impulse oscillometry 
provides a novel alternate effort independent technique.123 In chapter 3 data 
demonstrates impulse oscillometry to be a more sensitive marker than spirometry for 
the assessment of beta-blocker induced bronchoconstriction, and thus it is reassuring to 
find no significant adverse effects on R5% predicted following acute esmolol dosing.  
The findings of this analysis support previous evidence that intravenous esmolol can be 
given safely in mild-to-moderate asthma. 163 
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In chapter 3, acute propranolol dosing of 10 or 20mg in a cohort of mild-to-moderate 
controlled asthmatics resulted in a mean 4.7% reduction in FEV1% predicted and a 
mean 31.3% increase in R5% at 2 hours after propranolol dosing. Within the current 
analysis, by means of concurrent inhaled tiotropium administration, no significant 
worsening of FEV1% predicted or R5% predicted following first dose exposure with 
10mg of propranolol was seen. By means of significant reductions in supine heart rate 3 
hours post propranolol there is clear evidence of systemic cardiac beta-1-adrenoceptor 
blockade. 
 
It is well recognized that achieving optimal dosing of beta-blockers in clinical practice 
is challenging, with the tolerated doses of beta-blockers used in clinical practice often 
being substantially less than recommended.164 Although lack of dose optimization is 
likely to be due to multi-factorial, it may be assumed that dose intolerance and contra-
indications may have influenced beta-blocker dosing.  In asthmatics prescribed beta-
blockers, it is even more unlikely to achieve dose optimization due to clinical concerns 
of bronchospasm. 
 
This analysis has shown that up-titration of propranolol can be achieved in asthma, 
without any significant deterioration in FEV1% or R5% predicted at the time of first 
dose or up titration in the presence of concomitant tiotropium use.  
 
This randomized controlled trial, was originally designed to investigate the proposed 
therapeutic benefits of nonselective beta-blockade in asthma.165 Whilst the study did 
show any therapeutic benefits, the results allowed an evaluation of the safety of 
nonselective beta-blockade in asthma.  
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This results of this analysis should not be interpreted that on the basis of this data with 
oral propranolol that asthmatic patients should be given nonselective beta-blockers with 
tiotropium cover, when a cardio-selective oral agent such as bisoprolol is more likely to 
be tolerated, especially in the presence of inhaled tiotropium. Indeed recent data have 
indicated a role for regular tiotropium for use as long acting controller therapy in 
addition to inhaled corticosteroids.166  However the results of this study do raise the 
possibility that if a nonselective beta-blocker such as propranolol can potentially be 
tolerated in asthma, then so may a cardio-selective beta-blocker, thus potentially 
offering reassurance to those wishing to utilize the cardiovascular benefits of beta-
blockers in patients with asthma controlled on inhaled corticosteroids. This data cannot 
be applied to patients with more severe asthma. 
 
When assessing the benefits of beta-blocker use in the treatment of cardiovascular 
disease, asthmatic patients have generally not been studied due to the reluctance to use 
beta-blockers in these patients. However when reviewing evidence of beta-blocker use 
within another contra-indicated group who have more severe impairment of pulmonary 
function, namely chronic obstructive pulmonary disease, reduced mortality rates have 
been associated with beta-blocker use.116  It is unclear whether these benefits would be 
seen in an asthmatic population however limited evidence does suggest a reduction in 
two year mortality with beta-blocker use post-myocardial infarction.84 
 
In conclusion this analysis has shown that acute esmolol did not cause any worsening of 
pulmonary function in controlled mild-to-moderate asthmatics. Furthermore first dose 
exposure and subsequent up-titration with propranolol up to 80mg was achieved without 
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any significant adverse impact on pulmonary function, due to concurrent administration 
of the long acting muscarinic antagonist tiotropium. 
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CHAPTER 7: 
 
EFFECTS OF BETA-BLOCKERS 
IN THE TREATMENT OF 
CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE: A 
RETROSPECTIVE COHORT 
STUDY 
 
 
Study Aims 
1. Examine the use of beta-blockers in COPD and their impact on mortality. 
2. Examine the effects of beta-blocker use on hospital admissions and COPD 
exacerbations. 
3. Assess the effects of co-prescription of beta-blockers and beta-agonists in 
COPD patients. 
4. Assess the tolerability of beta-blocker use in COPD. 
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1. INTRODUCTION 
 
Chronic Obstructive Pulmonary Disease (COPD) and cardiovascular disease are 
intertwined due to the risk of smoking induced atherosclerosis.106   Despite the proven 
benefits of beta-blockers in hypertension, ischaemic heart disease and heart failure, 
there remains a reluctance to prescribe beta-blockers in individuals with concurrent 
COPD.118,167 
 
This thesis has evaluated the safety and tolerability of non-selective beta-blocker use in 
asthma and has demonstrated that non-selective beta-blockers may potentially be given 
relatively safely to selected individuals with mild-to-moderate asthma.  Considering that 
theoretically the extent of airway reversibility is less within COPD, assumptions could 
be made that the degree of potential beta-blocker induced bronchoconstriction is also 
less than that seen in asthmatic patients. 
 
COPD is a highly heterogeneous condition and recent evidence has shown that the 
degree of co-morbidities present appear to be independent of the degree of airway 
obstruction.108 The treatment of co-morbid cardiovascular disease in COPD is especially 
relevant given cardiac failure has been shown to be a leading cause of death in these 
patients.168 
 
In this regard the use of beta-blockers in individuals with COPD and cardiovascular 
disease has been shown to reduce rates of mortality in a series of observational 
studies.84,117 Whether the improved survival seen with beta-blockers in COPD is purely 
due to cardiovascular effects has been questioned. Recent evidence suggests that beta-
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blockers may improve survival and exacerbations in COPD patients without 
cardiovascular disease.116 
 
Whilst cardio-selective beta-blockers are assumed to target beta-1-adrenceptors whilst 
avoiding beta-2-adrenoceptors in the lung, so called cardio-selective beta-blockers, for 
example atenolol and bisoprolol are only relatively beta-1-selective and have been 
shown to exert significant beta-2-antagonsim at therapeutic doses, albeit to a lesser 
extent than non-selective beta-blockers such as propranolol.169-172   
 
Despite relative beta-adrenoceptor selectivity, it could be considered counterintuitive to 
co-prescribe both beta-blockers and beta-agonists in the same individual, even when 
they are targeting different organs.  Current COPD management guidelines advocate a 
stepwise approach using long acting bronchodilators (including beta-agonists) and 
inhaled corticosteroids to reduce exacerbations, improve symptoms and lung function.34  
Furthermore combination treatments involving long acting bronchodilators and inhaled 
corticosteroids have failed to show any significant improvement in mortality.173,174 
 
In this study the aim was to examine the use of beta-blockers in COPD, assessing their 
interrelationship with beta-agonists and other COPD medications and assess whether 
beta-blockers use improves mortality, hospital admissions and exacerbations when 
added to established stepwise inhaled therapy for COPD. 
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2. METHODS 
 
This study utilised the NHS Tayside Respiratory Disease Information System 
(TARDIS) to identify patients since January 2001 to January 2010 who had a diagnosis 
of COPD.  TARDIS is a disease specific database that was developed in 2001 to support 
primary care practitioners and secondary care respiratory physicians in managing 
patients with COPD in Tayside, Scotland.  Entry into TARDIS requires a diagnosis of 
COPD based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
Guidelines,175 comprising  patient demographics, respiratory symptoms, lung function 
and smoking history.  Data collected in the TARDIS database (including spirometry 
data) is performed at annual visits by specialist respiratory nurses. 
 
Data provided by the Health Informatics Centre, at the University of Dundee (HIC) on 
behalf of the Information Services Division of NHS Scotland, using Scottish morbidity 
records (SMR) allowed patient within NHS Tayside Health Board, Scotland who had 
experienced a hospital admission due to COPD to be identified. Discharge summaries 
with a diagnosis of COPD were used to identify respiratory related hospital admissions.  
International Classification of Disease (ICD-9, ICD-10) codes were used. 
 
Prescription data of respiratory and cardiovascular medications from the Tayside 
Community Prescription database was collected, as was history of death from the 
General Register Office for Scotland.  Deprivation was calculated for each patient from 
their postcode and applying the Scottish Index of Multiple Deprivation (SIMD). A 
health board specific deprivation index (HBSIMD) was calculated in relation to the 
local population.  A history of diabetes and admission to hospital due to cardiovascular 
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disease (including ischemic heart disease, heart failure and peripheral vascular disease) 
was identified using ICD-9 and ICD-10 codes.  All datasets were subsequently merged 
into a single dataset for analysis. 
 
Data provided to HIC by the Information Services Division of NHS Scotland undergoes 
data quality checks prior to release. The study was approved by the Tayside Medical 
Research Ethics Committee. 
 
Data analysis 
Patients were initially divided into two groups dependent on beta-blocker use. Kaplan 
Meier analysis with log-rank testing was performed to compare all-cause mortality 
dependent on beta-blocker use. Cox Proportional hazard regression analysis was used to 
calculate crude and adjusted hazard ratios and their 95% confidence intervals for all-
cause mortality associated with beta-blocker use and for cardio-selective and non-
selective beta-blockers. Adjusted hazard ratios were calculated after correction 
including the following covariates:  cardiovascular and respiratory hospital admissions, 
diabetes, smoking, age, sex and cardiac drug use (aspirin, statins, calcium channel 
blockers, ACE inhibitors), FEV1% predicted, resting Sa02 and deprivation index. A 
propensity score was calculated utilising covariates, influencing beta-blocker use and 
the Cox regression model was repeated in a subgroup of patients matched on propensity 
score. Time dependent analysis was also performed for the effects of beta-blocker use 
on all-cause mortality. 
 
Patients were then divided into sub-groups based on their maximal stepwise inhaled 
therapy and beta blocker use: inhaled corticosteroids (ICS) (group 1); ICS and long-
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acting beta-agonists (salmeterol or formoterol :LABA) (group 2); ICS and LABA and 
beta-blockers (BB) (group 3); ICS and LABA and long acting anti-muscarinic 
(Tiotropium :Tio) (group 4); ICS and LABA and Tio and BB (group 5); LABA/Tio (no 
ICS) (group 6); BB (no ICS) (group 7); ICS and BB (group 8); ICS and Tio (group 9) 
and LABA/Tio and BB (group 10).  The control group comprised those who had only 
received inhaled therapy with either short acting beta-agonist (salbutamol, terbutaline) 
or short acting anti-muscarinic (ipratropium).  Two or more sequential prescriptions 
were required for patients to be stratified into differing treatment groups. 
 
Cox proportional hazard regression analyses were then used to calculate crude and 
adjusted hazard ratios for all-cause mortality, hospital admissions due to respiratory 
disease and emergency oral corticosteroid use dependent on treatment groups in 
reference to the control group.   This was then repeated focusing upon death due to 
myocardial infarction and COPD as surrogate markers of cardiac and respiratory 
mortality respectively. Subgroup analyses were also performed for respiratory related 
hospital admissions specifically due to COPD exacerbation.  
 
When calculating hazard ratios for all-cause mortality, patients were censored if they 
were lost to follow up or reached the end of the study period (January 2010). For 
hospital admissions and oral corticosteroid use, treatment groups were calculated using 
prescription data prior to the respective event occurring, with censoring as described.   
 
Adjusted hazard ratios for mortality were calculated following correction after with the 
following covariates: cardiovascular and respiratory hospital admissions, diabetes, 
smoking, age at diagnosis, sex and cardiac drug use, FEV1, resting Sa02 and deprivation 
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index.  Additional models were developed to calculate adjusted hazard ratios, death due 
to COPD or myocardial infarction, hospital admissions due to respiratory disease, 
hospital admissions due to COPD and oral corticosteroid use. All hazard ratios were 
calculated from Cox regression models following forced entry of all available covariates 
to reduce residual confounding. For all tests, a two-sided P value of less than 0.05 was 
considered significant.  Analyses were performed using SPSS version 17.0. Chicago, 
Illinois. 
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3. RESULTS 
 
 
 
A total of 6,345 patients were identified through the TARDIS database.  Within this 
cohort, 5,977 were over 50 years of age and used for analysis. Patients were excluded 
from the analysis if they had a history of malignancy prior to their entry into TARDIS.  
Stratified by GOLD spirometry classification: 897 (15%) of patients were GOLD stage 
1 mean FEV1% (SD) 90.8 (9.4); 3287 (55%) of patients were GOLD stage 2 mean 
FEV1% (SD) 64.8 (8.3); 1494 (25%) of patients were GOLD stage 3 mean FEV1% (SD) 
40.9 (5.6);  299 (5%) of patients were GOLD stage 4 mean FEV1% (SD) 24.8 (4.6).  
Mean (SD) follow up was 4.35 (2.28) years. In total 779 patients received beta-blockers. 
Stratified by GOLD stage, beta-blocker use was; 151 patients were GOLD stage 1; 462 
were GOLD stage 2; 144 were GOLD stage 3 and 22 were GOLD stage 4. The mean 
(SD) age of patients at time of diagnosis of COPD (time of entry into TARDIS 
database) was 69.1 (9.4) years.  3048 (51%) of patients were male.  88% of beta-
blockers (BB) were cardio selective. All patients were receiving SABA +/- ipratropium 
including the control group.  Patient characteristics at study entry are illustrated in table 
13. 
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Treatment 
Groups 
Age  
(SD) 
Male   
n, (%) 
FEV1%   
(SD) 
SaO2   
(SD) 
Smoking 
Pack Years 
(SD) 
History of 
Cardiac 
Disease  
n,(%) 
History of 
Diabetes 
n,(%) 
ICS                   
(n=464) 
69.7 (9.8) 239 (51.5) 65.5 (19.5) 94.2 (10.9) 41 (16.5) 190 (40.9) 46 (9.9) 
ICS+BB               
(n= 71) 
71.7 (8.6) 36 (50.7) 64.2 (16.1) 93.3 (14.5) 39 (12.6) 51 (71.8) 18 (25.4) 
ICS+LABA  
(n= 996) 
68.9 (9.6) 547 (54.9) 62.7 (18.9) 92.5 (13.5) 41.2 (19.4) 429 (43.1) 148 (14.9) 
ICS+LABA+
BB   
(n= 143) 
68.8 (9.7) 70 (49) 65.7 (16.7) 94.2 (9.8) 41.5 (18.4) 96 (67.1) 25 (17.5) 
ICS+LABA+
Tio  (n= 
1857) 
68.3 (8.9) 972 52.3) 50.8 (17.1) 91.3 (11.6) 44.8 (16) 874 (47.1) 259 (13.9) 
ICS+LABA+
Tio+BB (n= 
187) 
68.1 (8.4) 77 (41.2) 52.8 (16.4) 92.6  (9.5) 45.1(18.6) 146 (78.1) 33 (17.6) 
LABA/Tio 
(no ICS) (n= 
526) 
69.9 (9.2) 263 (50) 60 (17.4) 93.5 (7.9) 45.7 (19.9) 220 (41.8) 67 (12.7) 
BB (no ICS)  
(n= 276) 
70.8 (8.8)  109 (39.5) 73.7 (16.3) 95.5 (7.1) 44.7 (16.4) 181 (65.6) 57 (20.7) 
ICS + Tio           
 (n= 158) 
69.1 (9.2) 70 (44.3) 55 (16.6) 93.2 (9.5) 44.1 (19.7) 73 (46.2) 25 (15.8) 
LABA/Tio 
+BB  
(n= 119) 
70.1 (8.1) 48 (40.3) 63.5 (14.2) 95 (2.1) 48.6 (22.3) 84 (70.6) 32 (26.9) 
Control group 
(n=1180) 
70.5 (10.2) 617 (52.3) 69.1 (18.3) 94.7 (7.9) 43.5 (16.5) 534 (45.3) 145 (12.3) 
 
Table 13. Patient demographics. Baseline characteristics at diagnosis of COPD -grouped according to 
final treatment group. Data unless otherwise stated presented as mean (SD) or mean (%). 
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Pulmonary function 
A subgroup analysis of n= 2712 was analysed where 6639 serial FEV1 and FVC 
measurements were available. Those patients being prescribed triple therapy with 
ICS+LABA +TIO had the lowest FEV1% predicted in keeping with increased disease 
severity. The addition of a beta-blocker did not have any deleterious impact when added 
to a regimen that included a long acting bronchodilator or inhaled corticosteroid (tables 
14 and 15) e.g. comparing ICS+LABA or ICS+LABA+TIO with and without beta-
blocker.  Moreover when comparing FEV1 values at the beginning and end of the study 
period there was no clinically significant deterioration in any treatment group including 
a beta-blocker with a clinically significant difference regarded as a 30ml/year reduction 
in FEV1 as found in the placebo limb of the UPLIFT study.176 
 
 
Table 14. FEV1 during study period. 
 
 
 
Treatment Groups (n) 
First FEV1(L) (SD) Last FEV1 (L) (SD) Mean Difference 
(95%CI) 
p value 
ICS (204) 1.64 (0.61) 1.63 (0.62) -0.01 (-0.04 to 0.03) 0.658 
ICS+BB (43) 1.55 (0.57) 1.58 (0.55) 0.03 (-0.05 to 0.10) 0.459 
ICS+LABA (459) 1.52 (0.60) 1.54 (0.62) 0.02 (-0.01 to 0.05) 0.123 
ICS+LABA+BB (89) 1.55 (0.54) 1.57 (0.55) 0.03 (-0.03 to 0.08) 0.355 
ICS+LABA+Tio  (753) 1.22 (0.51) 1.19 (0.51) -0.03 (-0.06 to -0.01) <0.001 
ICS+LABA+Tio+BB (88) 1.27 (0.50) 1.28 (0.53) 0.01 (-0.06 to 0.08) 0.749 
LABA/Tio (no ICS)  (197) 1.48 (0.58) 1.44 (0.57) -0.04 (-0.08 to -0.01) 0.016 
BB (no ICS) (276) 1.83 (0.53) 1.74 (0.55) -0.09 (-0.11 to -0.06) <0.001 
ICS+Tio (81) 1.37 (0.53) 1.40 (0.49) 0.03 (-0.03 to 0.09) 0.257 
LABA/Tio +BB (47) 1.67 (0.56) 1.65 (0.57) -0.02 (-0.09 to 0.04) 0.435 
Control (SABA+/-SAMA) 
(475) 
1.76 (0.62) 1.69 (0.59) -0.07 (-0.09 to -0.05) <0.001 
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Table 15. FVC during study period. 
 
 
All-Cause Mortality 
Evaluating the impact beta-blockers have on survival, Kaplan Meier analysis and log 
rank testing showed a significant improvement in overall survival for those that 
received beta-blockers (n=819) in comparison with those who did not (Chi-Square 
18.97, p<0.001), (See figure 23).  Following matched propensity scoring analysis, to 
balance associated covariates between groups, our study suggests that beta-blocker use 
is associated with a 22% reduction in mortality HR 0.78 (95%CI 0.67 to 0.92). Cox 
Regression with time dependent analysis comparing patients exposed to beta-blocker or 
no beta-blocker assessing effects on all-cause mortality, shows a significant overall 
effect; HR 0.92 (95%CI 0.85 to 0.96). 
 
 
 
Treatment Groups (n) 
First FVC(L) (SD) Last FVC (L) (SD) Mean Difference 
(95%CI) 
p value 
ICS (204) 2.75 (0.94) 2.78 (0.97) 0.03 (-0.03 to 0.09) 0.369 
ICS+BB (43) 2.58 (0.82) 2.71 (0.87) 0.13 (-0.02 to 0.28) 0.086 
ICS+LABA (459) 2.61 (0.94) 2.71 (0.97) 0.10 (0.05 to 0.14) <0.001 
ICS+LABA+BB (89) 2.63 (0.89) 2.69 (0.87) 0.06 (-0.05 to 0.15) 0.287 
ICS+LABA+Tio  (753) 2.46 (0.89) 2.48 (0.84) 0.02 (-0.01 to 0.06) 0.241 
ICS+LABA+Tio+BB (88) 2.40 (0.88) 2.50 (0.89) 0.10 (-0.01 to 0.20) 0.08 
LABA/Tio (no ICS)  (197) 2.67 (0.93) 2.66 (0.93) 0.01 (-0.07 to 0.05) 0.767 
BB (no ICS) (276) 2.91 (0.84) 2.80 (0.89) 0.11 (0.05 to 0.16) <0.001 
ICS+Tio (81) 2.48 (0.81) 2.59 (0.75) 0.11 (0.01 to 0.20) 0.043 
LABA/Tio +BB (47) 2.77 (0.93) 2.82 (0.95) 0.05 (-0.05 to 0.17) 0.297 
Control (SABA+/-SAMA) 
(475) 
2.90 (0.96) 2.86 (0.95) -0.04 (-0.09 to -0.02) 0.041 
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Figure 23. Kaplan-Meier estimate of probability of survival based upon beta-blocker use. 
 
When comparing cardio-selective beta-blockers with non cardio-selective beta-blockers 
there was no significant difference between groups (Chi-Square 0.77, p=0.378). 
N=2005 patients died during the study period equating to an annual death rate of 34%. 
Cox Proportional hazards ratios were calculated for each treatment group based upon 
stepwise management for COPD. At each comparison the adjusted hazard ratio for 
treatment groups including a beta-blocker were lower than the respective treatment 
group without a beta-blocker.  The crude hazard ratios for those patients on 
ICS+LABA+Tio with and without beta-blocker were 0.38 (95%CI 0.28 to 0.52) and 
0.54 (95%CI 0.48 to 0.61), whilst the adjusted hazard ratios for those patients on 
ICS+LABA+Tio with and without beta-blocker were 0.28 (95%CI 0.21 to 0.39) and 
0.43 (95%CI 0.38 to 0.48). The crude hazard ratios for treatment groups ICS+LABA 
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with and without beta-blocker were 0.43 (95%CI 0.31 to 0.60) and 0.67 (95%CI 0.59 to 
0.78), whilst the adjusted hazard ratios for treatment groups ICS+LABA with and 
without beta-blocker were 0.44 (95%CI 0.31 to 0.62) and 0.64 (95%CI 0.57 to 0.74). 
Finally the crude hazard ratios for treatment groups ICS with and without beta-blocker 
were 0.51 (95%CI 0.33 to 0.79) and 0.66 (95%CI 0.55 to 0.79), whilst the adjusted 
hazard ratios for treatment groups ICS with and without beta-blocker were 0.48 (95%CI 
0.31 to 0.74) and 0.69 (95%CI 0.58 to 0.83). Adjusted hazard ratios for all treatment 
groups and covariates used in the Cox regression model are illustrated in figure 24 and 
can also be found in table 16. 
 
Cardiac and Respiratory Mortality 
288 (14%) of patients who died had myocardial infarction whilst 625 (32%) had COPD 
recorded as their primary causes of death.  Similar benefits in reducing death due to 
myocardial infarction and COPD were seen when these patients were stratified by 
treatment group. For example for those patients on ICS+LABA+Tio and beta-blocker 
the adjusted hazard ratios for death due to myocardial infarction and COPD were: 0.25 
(95%CI 0.11 to 0.58) and 0.39 (95%CI 0.2 to 0.78) respectively, (see table 17). 
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Table 16. Adjusted hazard ratios for all-cause mortality. 
 
 
 
Treatment Groups 
 
Adjusted HR 95% CI 
ICS+LABA+Tio+BB  0.28 0.21 to 0.39 
ICS+LABA+Tio 0.43 0.38 to 0.48 
ICS+LABA+BB 0.44 0.31 to 0.62 
ICS+LABA 0.64 0.57 to 0.74 
ICS+BB 0.48 0.31 to 0.74 
ICS 0.69 0.58 to 0.83 
ICS +Tio 0.61 0.47 to 0.80 
LABA/Tio(no ICS) +BB 0.52 0.36 to 0.76 
LABA/Tio(no ICS) 0.71 0.59 to 0.84 
BB (no ICS) 0.65 0.51 to 0.83 
Covariates used in Cox Regression Model 
History of hospital admission due to 
Cardiovascular Disease 
2.04 1.84 to 2.27 
History of hospital admission due to 
Respiratory Disease 
2.38 2.16 to 2.62 
Age at study entry 1.05 1.05 to 1.06 
Sex (male) 1.19 1.09 to 1.31 
Smoking (Pack Years) 1.01 1.00 to 1.01 
History of Diabetes 0.91 0.80 to 1.03 
FEV1% Predicted 0.98 0.97 to 0.98 
Sa02 at rest 0.99 0.99 to 1.00 
Deprivation Index (HBSIMD) (1= most 
deprived) 
  
HBSIMD 1  0.99 0.89 to 1.11 
HBSIMD 2 1.02 0.88 to 1.19 
HBSIMD 3 0.88 0.76 to 1.02 
HBSIMD 4 0.85 0.73 to 1.00 
Cardiovascular Medications  
Aspirin 0.80 0.73 to 0.88 
Statins 0.89 0.81 to 0.97 
ACE Inhibitors 0.79 0.72 to 0.88 
Calcium Channel Blockers 0.71 0.64 to 0.78 
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Table 17. Adjusted hazard ratios for mortality due to myocardial infarction and COPD. 
 
 
 
 
 
 
Treatment Groups  
Mortality due to Myocardial 
Infarction 
N= 288 
Mortality due to COPD 
N= 625 
Adjusted 
Hazard Ratio 
95% CI Adjusted 
Hazard Ratio 
95% CI 
ICS+LABA+Tio+BB  0.25 0.11 to 0.58 0.39 0.20 to 0.78 
ICS+LABA+Tio 0.44 0.31 to 0.62 0.30 0.24 to 0.38 
ICS+LABA+BB 0.49 0.27 to 0.90 0.23 0.09 to 0.64 
ICS+LABA 0.53 0.37 to 0.76 0.52 0.40 to 0.68 
ICS+BB 0.46 0.19 to 1.13 0.25 0.06 to 0.99 
ICS 0.80 0.51 to 1.27 0.45 0.32 to 0.65 
ICS +Tio 0.63 0.29 to 1.37 0.39 0.25 to 0.61 
LABA/Tio(no ICS) +BB 0.54 0.25 to 1.16 0.38 0.12 to 1.20 
LABA/Tio(no ICS) 1.09 0.66 to 1.81 0.42 0.30 to 0.60 
BB (no ICS) 0.67 0.41 to 1.10 0.88 0.32 to 2.38 
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Emergency Oral Steroid Prescription 
3415 patients (57.1%) had at least one prescription of oral steroids during the study 
period. The adjusted hazard ratio for oral steroid prescription for those patients on 
ICS+LABA+Tio with and without beta-blocker were 0.31 (95%CI 0.22 to 0.43) and 
0.68 (95%CI 0.61 to 0.75). The adjusted hazard ratios for treatment group ICS+LABA 
with and without beta-blocker were 0.46 (95%CI 0.34 to 0.63) and 0.93 (95%CI 0.85 to 
1.03). The adjusted hazard ratios for ICS with and without beta-blocker were 0.51 
(95%CI 0.39 to 0.69) and 0.77 (95%CI 0.69 to 0.87). Adjusted hazard ratios for 
covariates used in the Cox regression model are illustrated in figure 25 and can also be 
found in table 18. 
 
Respiratory Hospital Admissions 
1608 patients (26.9%) had at least one hospital admission due to respiratory disease 
during the study period. The adjusted hazard ratio for hospital admission due to 
respiratory disease for those patients on ICS+LABA+Tio with and without beta- blocker 
were 0.32 (95%CI 0.22 to 0.44) and 0.70 (95%CI 0.61 to 0.80). The adjusted hazard 
ratios for treatment group ICS+LABA with and without beta-blocker were 0.39 (95%CI 
0.26 to 0.60) and 0.82 (95%CI 0.7to 0.96). The adjusted hazard ratios for ICS with and 
without beta-blocker were 0.36 (95%CI 0.22 to 0.58) and 0.79 (95%CI 0.66 to 0.95). 
Adjusted hazard ratios for covariates used in the Cox regression model are illustrated in 
figure 26 and can also be found in table 19. 
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Table 18. Adjusted hazard ratios for emergency oral steroid prescription. 
 
 
 
 
 
 
 
 
 
Treatment Groups 
 
Adjusted HR 95% CI 
ICS+LABA+Tio+BB  0.31 0.22 to 0.43 
ICS+LABA+Tio 0.68 0.61 to 0.75 
ICS+LABA+BB 0.46 0.34 to 0.63 
ICS+LABA 0.93 0.85 to 1.03 
ICS+BB 0.51 0.39 to 0.69 
ICS 0.77 0.69 to 0.87 
ICS +Tio 0.81 0.68 to 0.96 
LABA/Tio(no ICS) +BB 0.44 0.33 to 0.59 
LABA/Tio(no ICS) 0.67 0.59 to 0.76 
BB (no ICS) 0.39 0.32 to 0.48 
Covariates used in Cox Regression Model 
History of hospital admission due to 
Cardiovascular Disease 
1.14 1.06 to 1.22 
History of hospital admission due to 
Respiratory Disease 
2.01 1.87 to 2.16 
History of Diabetes 0.99 0.90 to 1.10 
Smoking (Pack Years) 1.00 0.99 to 1.01 
Age at study entry 1.01 1.00 to 1.02 
Sex (male) 0.95 0.89 to1.02 
FEV1% Predicted 1.00 0.99 to 1.01 
Sa02 at rest 1.01 1.01 to 1.02 
Deprivation Index (HBSIMD) (1= most 
deprived) 
  
HBSIMD 1  1.01 0.93 to 1.10 
HBSIMD 2 1.03 0.91 to 1.15 
HBSIMD 3 0.94 0.84 to 1.06 
HBSIMD 4 0.92 0.82 to 1.04 
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Table 19. Adjusted hazard ratios for hospital admissions due to respiratory disease. 
 
 
 
 
Treatment Groups 
 
Adjusted HR 95% CI 
ICS+LABA+Tio+BB  0.32 0.22 to 0.44 
ICS+LABA+Tio 0.70 0.61 to 0.80 
ICS+LABA+BB 0.39 0.26 to 0.60 
ICS+LABA 0.82 0.70 to 0.96 
ICS+BB 0.36 0.22 to 0.58 
ICS 0.79 0.66 to 0.95 
ICS +Tio 0.71 0.53 to 0.96 
LABA/Tio(no ICS) +BB 0.31 0.19 to 0.51 
LABA/Tio(no ICS) 0.70 0.58 to 0.85 
BB (no ICS) 0.31 0.22 to 0.44 
Covariates used in Cox Regression Model 
History of hospital admission due to 
Cardiovascular Disease 
1.87 1.69 to 2.09 
History of Diabetes 0.99 0.87 to 1.14 
Smoking (Pack Years) 1.00 0.99 to 1.01 
Age at study entry 1.01 1.01 to 1.02 
Sex (male) 0.84 0.76 to 0.93 
FEV1% Predicted 0.98 0.97 to 0.99 
Sa02 at rest 0.99 0.98 to 1.01 
Deprivation Index (HBSIMD) (1= most deprived)   
HBSIMD 1  1.07 0.95 to 1.21 
HBSIMD 2 1.26 1.07 to 1.48 
HBSIMD 3 1.04 0.88 to 1.23 
HBSIMD 4 0.92 0.77 to 1.11 
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 COPD Hospital Admissions 
1094 (68%) of those who had a hospital admission due to respiratory disease, had a 
primary coded diagnosis of COPD exacerbation.  Similar trends of improvement were 
seen as with all hospital admissions due to respiratory disease. The adjusted hazard ratio 
for hospital admission due to respiratory disease for those patients on ICS+LABA+Tio 
with and without beta-blocker were 0.25 (95%CI 0.14 to 0.42) and 0.77 (95%CI 0.65 to 
0.91). The adjusted hazard ratios for treatment group ICS+LABA with and without 
beta-blocker were 0.37 (95%CI 0.22 to 0.64) and 0.81 (95%CI 0.67 to 0.97). The 
adjusted hazard ratios for ICS with and without beta-blocker were 0.24 (95%CI 0.20 to 
0.49) and 0.69 (95%CI 0.54 to 0.87). 
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4. DISCUSSION 
 
Through matched propensity scoring analysis, a 22% overall reduction in all-cause 
mortality with beta-blocker use was demonstrated in this study.  Importantly this study 
also suggests there may be benefits when beta-blockers are added to established 
stepwise inhaled treatment regimes for COPD in reducing all-cause mortality. Through, 
Cox proportional hazard regression, the additive benefits of beta-blockers was 
demonstrated independent of other cardiovascular medications and history of overt 
cardiovascular disease (ischaemic heart disease, heart failure, peripheral vascular 
disease). These findings suggest that beta-blockers may add benefits to reducing 
mortality in COPD in addition to the benefits gained by addressing cardiovascular risk. 
 
The baseline demographics of the treatment groups demonstrated similar levels of social 
deprivation. Deprivation is known to influence mortality rates and when considering 
beta-blocker use in heart failure, those individuals of worse deprivation are less likely to 
be treated.177 The Scottish Index of Multiple Deprivation was used to calculate the 
deprivation score used in our cohort. 6.9% of the most deprived areas in Scotland are 
located within Tayside Health Board.178 
 
Previous studies have focused upon the presence or absence of beta-blockers and their 
influence on mortality and hospitalisations.116,179 In the study by Rutten et al. they found 
that the benefit on mortality seen with beta-blockers was preserved in those individuals 
who were concurrently prescribed two or more pulmonary drugs or who were using 
inhaled beta-2 agonists or anti-muscarinics.  However their analysis did not stratify 
according to stepwise treatment regimens and in particular for LABA use.  This issue is 
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pertinent given the potential for co-prescription of agonists and antagonists medications 
with theoretical interactions. 
 
FEV1 has previously been shown to decline over time.180  Using a 30ml per year 
reduction as observed in the placebo limb of the Understanding Potential Long-term 
Impacts on Function with Tiotropium (UPLIFT) study for reference, in this study there 
was no clinically significant decline in mean FEV1 over time in each treatment group.176  
Within treatment groups, decline in FEV1 was observed in individuals, however the 
percentage of patients where decline was observed were consistent when comparing 
treatment groups. 
 
In line with previous studies a benefit on all-cause mortality in COPD patients taking 
statins and ACE inhibitors was found.113,181 As expected this study showed significant 
mortality reductions as evidenced by hazard ratios with aspirin 0.8 (95%CI 0.73 to 
0.88), statins 0.89 (95%CI 0.81 to 0.97), ACE inhibitors 0.79 (95%CI 0.72 to 0.88) and 
calcium channel blockers 0.71 (95%CI 0.64 to 0.78).  These findings demonstrate the 
importance of recognising COPD patients as having a high risk of developing 
cardiovascular disease. 
 
This data showed the same trends in terms of additive benefits with beta-blockers to 
stepwise inhaled therapy, for all-cause mortality, oral steroid prescriptions and 
admissions, which may add support to the value of using beta-blockers in COPD.  
Although it could be suggested that the reduction observed in all-cause mortality seen 
with beta-blocker use is attributable to their cardiovascular effects, similar benefits were 
seen in reducing mortality due to COPD and myocardial infarction, although some 
  
164 
hazard ratios within groups failed to reach statistical significance.  These observations 
along with the reductions in hospital admissions and emergency oral steroid use are by 
definition more difficult to be explained by improving cardiovascular risk. 
 
This begs the key question as to whether beta-blockers confer independent beneficial 
pulmonary effects in COPD. With this in mind one possibility is that up-regulation of 
beta-2-adrenoceptors by chronic beta-blockade may improve the effectiveness of beta-
2-agonists.  Despite the majority of beta-blockers in this study being relatively cardio-
selective, drugs such as atenolol and bisoprolol even at therapeutic doses have been 
shown to exert a significant degree of beta-2-adrenoceptor antagonism, which in turn 
may result in beta-2-adrenoceptor up-regulation. Thus from a pharmacological point of 
view up-regulation of beta-2-adrenoceptors by cardio-selective beta-blockers seems 
plausible.  In this regard there was no worsening of FEV1 or FVC seen when for 
example comparing groups receiving ICS+LABA vs. ICS+LABA +BB and 
ICS+LABA+Tio vs. ICS+LABA+Tio+BB.  Ind et al, has demonstrated  that anti-
muscarinic therapy prevents beta-blocker induced bronchoconstriction in asthmatics .10  
This in turn would suggest a rationale for using tiotropium when adding a beta-blocker 
to a patient with COPD, aside from the known benefits of tiotropium on exacerbations 
and symptoms.176 
 
TARDIS is an example of a NHS COPD database, routinely used to guide COPD 
management in Tayside. The strength of this disease specific database lies within all 
patients having a diagnosis of COPD made by a primary or secondary care physician on 
the basis of GOLD guidelines. Since 2001, patients with COPD have been invited to be 
included in the database, TARDIS has been used as the basis for previous published 
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COPD research thereby providing us with an unselected community population of 
COPD patients for analysis.135   
 
Confounding by indication is a limitation when performing observational studies of this 
nature.  As a COPD disease specific database was used for patient identification 
unfortunately the specific indication for beta-blocker prescription was unknown. In 
order to address this, a Cox proportional hazard regression model that corrected for all 
available influential covariates was used. Pointedly the study evaluated the effects of 
beta-blockers on all-cause mortality independently of cardiovascular outcomes 
including cardiac drug prescription and overt cardiovascular disease measured by 
hospital admissions due to ischemic heart disease, heart failure and peripheral vascular 
disease, although a history of hypertension was unavailable for analysis from the 
database.  
 
Furthermore when assessing the impact of beta-blocker use on all-cause mortality, 
matched propensity scoring analysis suggested a beneficial effect with beta-blocker use. 
Propensity score matched analysis is designed to minimize the effects of confounding 
by indication.182 Time dependent analysis also confirmed the beneficial effects of beta-
blockade in this analysis. 
 
An age cut-off of 50 years and above was used, in order to alleviate any concerns that 
younger patients than 50 years may be regarded as asthmatics. An age cut off of 45 
years and above has been use in previous COPD observational studies.116 Furthermore 
when analysing all patients in the dataset regardless of age (n=6345), similar trends in 
survival as with the study cohort (n=5977) were seen. For example in the 
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ICS+LABA+Tio and beta-blocker group the adjusted hazard ratio for all-cause 
mortality was 0.33 (95%CI 0.24 to 0.44) in the extended dataset compared with 0.28 
(95%CI 0.21 to 0.39) in the study population. 
 
In summary this study has shown that beta-blockers (predominantly cardio-selective) 
may confer reductions in mortality, exacerbations and hospital admissions in patients 
with COPD, in addition to the benefits attributable to addressing cardiovascular risk. 
These additive benefits were seen across a spectrum of inhaled step wise therapy, 
including inhaled corticosteroids, long acting beta-agonists and long acting anti-
muscarinics, and did not result in any worsening of pulmonary function in the study 
cohort.   
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5. CRITIQUE 
This study attempted to examine the potential beneficial effects of beta-blocker use on 
survival in COPD utilising a NHS disease specific database, namely TARDIS.  Whilst 
TARDIS is used as a clinical tool for the management of COPD, diagnostic accuracy 
has to be considered when using this dataset for observational studies with potential 
clinical implications.  In order to be included within TARDIS, patients had to be 
diagnosed with COPD by either a primary or secondary care physician. As a result there 
could potentially be diagnostic error as patients considered to have COPD, by a general 
practitioner could for example have an alternative respiratory disease such asthma with 
a history of smoking which may have been identified by the secondary care physician 
with the support of extensive pulmonary function tests available in a hospital setting.   
However despite the possibility for misdiagnosis, this large NHS dataset provides 
means of examining mortality benefits which otherwise could not be performed due to 
the lack of randomised controlled trial data. 
 
This study suggested survival benefits with beta-blocker use in COPD.  These results 
however must be interpreted with caution.  Although a disease specific dataset was 
used, this study was retrospective and observational in design and therefore the risk of 
bias exists. Although statistical methods attempted to reduce this risk, bias remains and 
observational studies of this nature should not be used to change clinical practice, but 
rather act as a stimulus to performing randomised controlled trials.  
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CHAPTER 8: 
 
DISCUSSION 
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DISCUSSION 
The aim of this thesis was to evaluate the use of beta-blockers in the treatment of 
asthma and COPD. To address this topic this thesis was divided into two distinct 
sections. Firstly proofs of concept, randomised controlled trials, evaluating both non-
selective and cardio-selective beta-blockade in asthma were performed. In addition to 
this health informatics datasets were utilised to perform a large observational study of 
beta-blocker use in COPD. 
 
Within this thesis two distinct proof of concept studies were performed assessing beta-
blocker use in asthma. The first study was designed primarily with patient safety as its 
major focus. The primary aim of this study was to assess the degree of beta-blocker 
induced bronchoconstriction following acute dosing with relatively low doses of oral 
propranolol in mild-to-moderate asthmatics.  The results of this study were fundamental 
in helping to develop a research protocol by which the subsequent chronic dosing of 
beta-blockers could be evaluated safely.  
 
By establishing whether acute propranolol dosing would prevent subsequent salbutamol 
and ipratropium recovery, following histamine challenge. The serious concerns of 
whether concurrent non-selective beta-blockade would result in a suboptimal 
bronchodilator response during an asthma exacerbation with potentially dangerous 
consequences were addressed. Reassuringly this study showed that staged salbutamol 
and ipratropium produced a full recovery after histamine induced bronchoconstriction 
following acute beta-blockade with either 10 or 20mg of oral propranolol.  Since the 
greatest risk of beta-blockade is after first dose, these findings offered reassurances with 
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regards to evaluating chronic beta-blockade as a potential treatment for mild-to-
moderate asthma. 
 
In addition to assessing the effects of acute beta-blockade on subsequent salbutamol 
reversibility, the primary outcome of this study was whether concurrent intravenous 
hydrocortisone would result in augmented bronchodilator reversibility.  It was 
hypothesised that hydrocortisone may partially reduce the effects of acute beta-blockade 
and improve the effects of nebulised salbutamol due its acute facilitatory effects on 
beta-2-receptors within 3 hours of administration.47  The study however failed to show 
any beneficial effects of hydrocortisone versus placebo.  However it is noted that in the 
scenario of patient having an asthma exacerbation whilst concurrently receiving beta-
blockers, it would still be prudent to give acute systemic corticosteroid to treat any 
associated worsening of airway inflammation. 
 
Performing studies of beta-blocker use in asthma contradicts established dogma that 
beta-blockers should never be given to asthmatics.  Therefore performing any study of 
beta-blocker use is ethically challenging. Adopting   first   principles   of   “Primum non 
nocere”  substantial ethical review was applied by the local ethics board to these study 
protocols prior to approval.  When devising each research protocol, every available 
safety measure was adopted in order to reduce the risk to the individual participant.  
Within each study protocol, only asthmatics with mild-to-moderate disease were 
recruited. Individuals had to have preserved lung function by means of an FEV1 greater 
than 80% predicted and be free of any exacerbation within the preceding 6 months. 
Furthermore participants had to be taking inhaled corticosteroids.  Despite these safety 
measures, following ethical review, although it was accepted that the likelihood of 
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adverse events from beta-blocker use were small, there was potential for serious adverse 
events including severe asthma exacerbation and death, subsequently these risks were 
included within study participant information sheets. 
 
Spirometry has historically been used to assess the degree of bronchoconstriction of 
associated with beta-blocker use in asthma.61 In this thesis, relatively low doses of 
propranolol were used. Whilst this approach increased the safety of the research 
protocols, there were concerns that standard spirometry may prove to be too insensitive 
in identifying bronchoconstriction.  In view of this, the novel technique of impulse 
oscillometry (IOS) was used. As IOS is effort independent method of assessing 
resistance, it is commonly used in children thereby avoiding the forced expiratory 
maneuvers required by spirometry.151,152  In this thesis the relative sensitivities of IOS in 
comparison with spirometry showed that following acute propranolol dosing, airway 
resistance at 5HZ (R5) showed a greater magnitude of change in comparison with FEV1 
(4.7% versus 31.3%) post propranolol at the same time point and visit.  Furthermore 
when accounting for the variability of each test the standardised response mean for R5 
versus FEV1 was  greater,  thereby  demonstrating  the  better  “signal  to  noise  ratio”.  These  
findings demonstrated the usefulness of IOS when assessing beta-blocker induced 
bronchoconstriction, in addition to standardised spirometry. 
 
The second study within this thesis was the first placebo-controlled trial of beta-blocker 
use in asthma to be recorded within the literature.  The study was designed to assess the 
effects of chronic non-selective beta-blockade with oral propranolol as add on to inhaled 
corticosteroids in stable persistent asthmatics.  
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Once again the safety of participants was a fundamental concern. Similar inclusion 
criteria were applied to the acute dosing study based upon the lack of adverse events 
seen following acute propranolol dosing. Given the greatest theoretical risk of beta-
blocker induced bronchoconstriction being after first dose exposure, a gradual dose 
titration regime was used.  As previously described, anti-cholinergic blockade with 
tiotropium was given concurrently during the dose titration phase to reduce the 
associated risks of bronchospasm.10  As part of the dose titration regime, this involved 
participants attending the department on a weekly basis for an observed dose up-
titration. Study medication was also dispensed on a weekly basis, in order to reduce the 
possibility of dosing errors. 
 
Originally based upon the previous open label studies it was planned to investigate the 
effects of the non-selective beta-blocker nadolol versus placebo on airway hyper-
responsiveness in mild-to-moderate asthmatics.102 However it transpired that the lowest 
dose of nadolol available in the UK is 80mg compared to 10mg for propranolol, which 
made initial dose titration possible with nadolol difficult, costly and time consuming for 
pharmaceutical reformulation. Furthermore nadolol is not routinely used in the UK and 
therefore the effects of propranolol were deemed to be of greater clinical relevance. 
Therefore following approval by the funding body Chief Scientist Office, nadolol was 
changed to propranolol. 
 
Propranolol and nadolol are both non-selective beta-blockers with similar 
pharmacological properties. Both drugs exhibit in-vitro inverse agonist activity (i.e. an 
ability to effectively switch off the receptor), as well acting as conventional competitive 
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receptor antagonists. Indeed propranolol exhibits a slightly higher beta-2 receptor 
binding affinity compared to nadolol.59 
 
In order to further enhance the safety of the chronic dosing study, an unblinded esmolol 
challenge visit was performed prior to randomisation to oral propranolol or placebo.  
This visit was performed on the pre-requisite of the Chief Scientist Office following 
review of the study proposal. The addition of this visit was designed in order to identify 
potential asthmatic participants highly susceptible to beta-blocker induced 
bronchoconstriction.  Esmolol is a highly cardio-selective beta-blocker. Therefore 
following acute esmolol dosing, any individual that demonstrated evidence of 
significant bronchoconstriction, with a fall in FEV1 by 20% would not proceed to non-
selective beta-blockade. Reassuringly no individual that underwent esmolol challenge 
demonstrated significant bronchoconstriction as measured by either spirometry or 
impulse oscillometry thereby inferring that esmolol could potentially be safely 
administered as clinically indicated to controlled ICS treated asthmatics. 
 
Due to unexpected national supply shortages of esmolol, following approval, the 
esmolol challenge visit was removed from the chronic dosing study protocol. This 
resulted in only 12 of the 18 participants receiving an esmolol challenge prior to chronic 
dosing with oral propranolol. Whilst it would have undoubtedly been preferable for 
each participant to undergo esmolol challenge testing, due to the lack of any significant 
beta-blocker induced bronchoconstriction being seen in the 12 completed participants it 
is unlikely that any bronchospasm would have been seen in the remaining participants. 
Furthermore due to the significantly different beta-adrenoceptors affinities displayed by 
both propranolol (beta1:beta2 selectivity ratio = 1:8) and esmolol (beta1:beta2 
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selectivity ratio =34:1), it is unlikely that the effects of esmolol challenge would fairly 
predict what may happen with propranolol. 
 
This thesis failed to demonstrate any therapeutic benefits with non-selective beta-
blocker use on airway hyper-responsiveness in asthma. Based upon previous work by 
Hanania et al, the study was designed to evaluate the potential beneficial effects on 
airway hyper-responsiveness demonstrated in previous open label studies.102,104 The 
lack of observed beneficial effects with propranolol in comparison to the proposed 
benefits demonstrated with nadolol is intriguing and could be attributable to several 
factors. 
 
Firstly the significance of randomised placebo controlled trials in comparison to open 
label studies should not be underestimated. However the effects of nadolol were 
reproduced in two distinct open label studies both showing an improvement in airway 
hyper-responsiveness to methacholine in comparison with baseline.102,104  In this thesis 
in  addition to demonstrating no improvement in AHR versus placebo, propranolol also 
failed to show any improvement in AHR in comparison with baseline measurements. 
 
Whilst nadolol and propranolol have similar pharmacological profiles, it is conceivable 
that an improvement in AHR would have been seen in this current study if nadolol had 
been used.  Originally the concept of putative beneficial effects of chronic beta-blocker 
use in asthma was based upon the concept of inverse-agonism.  Both propranolol and 
nadolol both display inverse agonist properties and therefore are able to decrease beta-2-
adrenoceptor  activity  below  basal  level  and  essentially  “switches  off”  the  receptor,  thus  
displaying negative efficacy.32 Prolonged treatment with inverse agonists, by reducing 
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constitutive receptor activity, would permit the system to resensitize and up-regulate 
receptors.96 It was proposed that up-regulation of the beta-2-adrenoceptors would result 
in reductions in acetylcholine release and an improvement in airway hyper-
responsiveness.  The lack of therapeutic benefit with propranolol in this thesis suggests 
that inverse agonism is not the only concept potentially responsible for the benefits 
previously seen with nadolol. 
 
As previously discussed beta-2-adrenoceptor signals via several pathways including the 
release of cAMP pathway with subsequent airway smooth muscle relaxation and the 
activation of beta-arrestin at the epithelial cells which in asthma has been shown to be 
pro-inflammatory.15,27 
 
Whilst endogenous ligands such as noradrenaline stimulate both cAMP release and 
beta-arrestin, it has been proposed that other ligands may preferentially activate one 
pathway over another, such is the case with salmeterol.183 The term   ‘biased  agonism’  
has been proposed to describe preferential activation of differing pathways via the same 
receptor.184  In addition to beta-agonists, certain beta-blockers have been shown to 
display beta-2-adrenoceptor ligand bias. 
 
Carvedilol has previously been shown to activate beta-arrestin signaling while shutting 
down the cAMP pathway.159 Furthermore propranolol has also been suggested to have 
similar signaling properties to carvedilol, which would result in worsening airway 
inflammation due to the inflammatory effects on airway epithelial cells. This is in 
comparison with nadolol with evidence supporting an inactivation of the beta-arrestin 
pathway with nadolol.159 Evidence does however exist that propranol may reduce beta-
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arrestin activation. In a study by Carter et al. isoprenaline-stimluated beta-arrestin 
activation was antagonised by propranolol.185 The suggestion therefore that the putative 
benefits seen on airway hyper-responsiveness with nadolol and not propranolol may be 
due to beta-arrestin signaling is uncertain. 
 
When comparing the differential effects displayed on airway hyper-responsiveness 
observed with chronic nadolol and propranolol dosing, the major difference between 
each study was the demographics of each respective study cohort.  Whilst the previous 
benefits of nadolol were displayed in steroid naïve asthmatics, the study discussed in 
this thesis assessed the chronic dosing effects of propranolol in asthmatics controlled on 
inhaled corticosteroids. It is therefore plausible that the lack of benefit seen with 
propranolol was due to the study design. Whether the presence of concurrent ICS has 
masked any potential benefits on AHR is uncertain, and thus the logical next step is to 
examine the possibility of steroid sparing effects of non selective beta-blockade,186 
examining whether adding propranolol to a lower dose of ICS would be as effective as 
increasing the dose of ICS alone.  This study is now underway. 
 
The clinical decision to include steroid treated asthmatics was based primarily upon 
safety grounds. Furthermore one could argue that investigating the effects of non-
selective beta-blockers in steroid naive asthmatics is clinically irrelevant, as it is 
unlikely that clinicians would ever consider giving a beta-blocker as monotherapy in 
asthma.  There is however a clinical trial currently investigating the effects on AHR 
with nadolol versus placebo in mild ICS naïve asthmatics (NCT01804218). 
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What is arguably more clinically relevant is that in the presence of concomitant 
tiotropium during dose titration, carefully selected controlled asthmatic patients are able 
to tolerate non-selective beta-blockade. This in turn might infer that cardio-selective 
agents might also be safely administered to controlled ICS treated asthmatics, thereby 
providing the means for potentially improving treatment of cardiovascular disease in an 
otherwise contra-indicated cohort. 
 
Addressing comorbidities in the overall management of the COPD patient is of great 
significance given the high rates extra-pulmonary complications, including myocardial 
infarction, stroke, lung cancer, depression, and osteoporosis that can occur. COPD and 
cardiovascular disease are undoubtedly linked due to the risk of smoking related 
atherosclerosis.106  However studies have also shown that the presence of COPD, 
independent of cigarette smoking substantially increases the risk of hospitalisation and 
death.107,187 Furthermore cardiovascular disease is the most common comorbidity and 
leading cause of hospitalisation in patients with mild to moderate COPD.187 
 
As previously discussed, beta-blockers are integral in the management of hypertension, 
ischaemic heart disease and heart failure. Furthermore previous observational studies 
have shown the potential benefits of beta-blocker use in COPD.84,116,119 The primary 
purpose of the study included in this thesis was to evaluate whether the proposed 
beneficial effects of beta-blockade in COPD could be reproduced. In addition, the 
interaction between beta-blockers and concurrent inhaled COPD medication including 
long–acting beta-agonists was assessed.  This study showed that following matched 
propensity scoring a 22% overall risk reduction in mortality was seen with beta-blocker 
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use in COPD.  When stratified by concurrent inhaled therapy, there was an increasing 
survival benefit throughout treatment groups, with the greatest benefit seen in the most 
severe patients treated with combination, inhaled corticosteroids, long-acting beta-
agonists and long-acting muscarinic antagonists. 
 
With regards to the management of heart failure beta-blocker use reduces mortality and 
morbidity by their impact on sympathetic and neurohumoral activation.188  
Neurohumoral activation refers to increased activity of the sympathetic nervous system, 
renin-angiotensin system, vasopressin and atrial natriuretic peptide, and has been 
proposed as a potential cause of systemic inflammation in COPD patients.189 In a study 
by Heindl et al, using microneurography of the peroneal nerve, sympathetic nerve 
activity was twice as high in COPD patients in comparison with matched healthy 
controls.190 Volterrani et al. have also described reduced heart rate variability in 
normoxaemic COPD patients versus healthy controls.191 Reduced heart rate variability 
may reflect excessive sympathetic activity and is a strong predictor of mortality post-
myocardial infarction.192 It could therefore be speculated that the proposed benefits of 
beta-blocker use in COPD are due to a reduction in sympathetic activity. 
Although the study included in this thesis, like other similar observational studies 
suggests a proposed benefit of beta-blocker use in COPD, results from a retrospective 
analysis should not be used in order to recommend changes to clinical practice, but to 
act as a stimulus to further research.   Within this current analysis, Cox proportional 
hazard regression with matched propensity was used with all available co-variates, 
thought to influence the potential outcome included with the regression model.  
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Despite these measures the potential for bias within the study results remains.  Immortal 
time bias is a common criticism of observational studies,193 and has been suggested as a 
contributing factor to the proposed beneficial effects of beta-blockers in COPD.194 
Immortal time bias is suggested when an individual has to survive the period from their 
inclusion in a study until they receive a second prescription to be considered exposed to 
the study drug.193 Time-dependent analysis attempts to correct for this potential bias. 
When the corresponding manuscript for this study was published, time-dependent 
analysis was not included. Since publication, the importance of considering immortal 
time bias was acknowledged and subsequently time-dependent analysis been included 
within this thesis.  Importantly time-dependent analysis continues to show a survival 
benefit with beta-blocker use in COPD, HR 0.92 (95%CI 0.85 to 0.96). In addition to 
this a further analysis by Rutten et al in acute bronchitis, (including COPD patients) 
including time-dependent analysis has continued to show a survival benefit with beta-
blocker use.195 
 
Given the potential benefits of beta-blocker use in COPD, other studies have examined 
differing aspects of their use that is relevant to clinical practice.  Co-prescription of both 
beta-agonist inhalers and beta-blockers may seem counterintuitive to the clinician in the 
management of COPD. This thesis has already demonstrated that beta-blockers 
treatment does not prevent salbutamol reversibility in asthma. Also co-prescription of 
both beta-blockers and beta-agonists appear to have increased survival benefit in COPD 
in comparison with beta-agonists alone.  Stefan et al. examined the effects of continuing 
beta-blockers in those admitted with an exacerbation of COPD, showing that cardio-
selective beta-blockers could be safely continued at the time of a COPD exacerbation.196 
No association between beta-blocker therapy and in-hospital mortality OR 0.88 (95%CI 
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0.71 to 1.09) or 30-day readmission OR 0.96 (95%CI 0.89 to 1.03) was seen. However, 
when compared with cardio-selective beta-blockers, non-selective beta-blockers use 
was associated with an increased risk of 30-day readmission (OR 1.25, 95% CI 1.08 to 
1.44).196   
 
Despite being integral to the treatment of ischaemic heart disease, beta-blockers remain 
under used in COPD patients who suffer a myocardial infarction. In a 10 year 
retrospective study of 6290 patients admitted with an acute myocardial infarction, 
patients with COPD were less likely to be treated with beta-blockers than patients 
without COPD. Patients with COPD were at higher risk for dying during hospitalization 
(13.5% vs 10.1%) and at 30 days after discharge (18.7% vs 13.2%).197 
The potential role of beta-blockers in acute myocardial infarction in COPD patients is 
further highlighted by a recent study from Quint et al.198 In 1063 patient with COPD, 
with a median follow up of 2.9 years, beta-blocker use either prior to, or at the time of 
hospital admission, for myocardial infarction was associated with significantly 
improved survival, HR 0.59 (95%CI 0.44 to 0.79) and HR 0.50 (95%CI 0.36 to 0.69) 
respectively.198 
The degree of evidence suggesting a potential benefit of beta-blocker use in COPD is 
encouraging. Due to the size of study cohort required to prospectively examine the 
effects of beta-blocker use on mortality in COPD by means of a randomised controlled 
trial, it is entirely possible that a study of this nature may be ever performed.  However 
in the first instance if the safety and tolerability of beta-blocker use can be demonstrated 
within COPD patients, this may act as supporting evidence for the treatment of 
cardiovascular co-morbidities with beta-blockers in COPD patients. 
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CONCLUSIONS 
 
1. Acute dosing of either 10 or 20mg of oral propranolol caused a small but 
significant deterioration in airway calibre in mild-to-moderate asthmatics, which 
was more evident with impulse oscillometry rather than spirometry. 
Bronchodilator reversibility with nebulised salbutamol and ipratropium 
produced a full recovery of FEV1 and airway resistance after acute histamine 
induced bronchoconstriction in the presence of acute beta-blockade. Intravenous 
hydrocortisone did not potentiate salbutamol recovery post-histamine challenge. 
2. Acute cardio-selective beta-blockade with intravenous esmolol (0.5mg/kg) did 
not cause any worsening of pulmonary function measured by spirometry and 
impulse oscillometry and may therefore be safe to use in mild-to-moderate 
asthmatics controlled on inhaled corticosteroids. 
3. Chronic dosing of 6 to 8 weeks of oral propranolol with a maximum dose of 
80mg daily did not show any improvements in airway hyper-responsiveness to 
bronchial challenge testing. No worsening of asthma control or quality of life 
was observed with only a small effect on pre-challenge pulmonary function. 
This thesis has shown that by means of a placebo controlled design, that the non-
selective beta-blocker propranolol may potentially be safe to use in mild-to-
moderate asthmatics controlled on inhaled corticosteroids receiving concomitant 
inhaled tiotropium. 
4. This thesis has shown that the use of beta-blockers in COPD patients may 
potentially confer reductions in mortality, exacerbations and hospital 
admissions, in addition to the benefits attributable to addressing cardiovascular 
risk. These additive benefits were seen across a spectrum of COPD severity.  
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